SA516371189B1 - مركب صيدلاني واستخدامه العلاجي لتثبيط بروتين raf لعلاج السرطان - Google Patents

Info

Publication number

SA516371189B1

SA516371189B1 SA516371189A SA516371189A SA516371189B1 SA 516371189 B1 SA516371189 B1 SA 516371189B1 SA 516371189 A SA516371189 A SA 516371189A SA 516371189 A SA516371189 A SA 516371189A SA 516371189 B1 SA516371189 B1 SA 516371189B1

Authority

SA

Saudi Arabia

Prior art keywords

disorder

cancer

braf

compound

treatment

Prior art date

2013-11-25

Links

• Espacenet
• Global Dossier
• Discuss

• 150000001875 compounds Chemical class 0.000 title claims abstract description 286
• 206010028980 Neoplasm Diseases 0.000 title claims abstract description 163
• 201000011510 cancer Diseases 0.000 title claims abstract description 85
• 238000011282 treatment Methods 0.000 title claims description 195
• 230000001225 therapeutic effect Effects 0.000 title description 22
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 213
• 208000035475 disorder Diseases 0.000 claims abstract description 151
• 239000000203 mixture Substances 0.000 claims abstract description 68
• -1 3-oxo-4H-pyrido[2,3-b]pyrazin-8-yl Chemical group 0.000 claims abstract description 38
• 206010061218 Inflammation Diseases 0.000 claims abstract description 22
• 230000004054 inflammatory process Effects 0.000 claims abstract description 20
• 230000002062 proliferating effect Effects 0.000 claims abstract description 20
• 208000036142 Viral infection Diseases 0.000 claims abstract description 13
• 230000009385 viral infection Effects 0.000 claims abstract description 13
• 208000026278 immune system disease Diseases 0.000 claims abstract description 9
• 230000003176 fibrotic effect Effects 0.000 claims abstract description 7
• 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 claims description 150
• 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 claims description 150
• 238000000034 method Methods 0.000 claims description 120
• 230000035772 mutation Effects 0.000 claims description 98
• 230000037361 pathway Effects 0.000 claims description 71
• 102000016914 ras Proteins Human genes 0.000 claims description 67
• 201000001441 melanoma Diseases 0.000 claims description 64
• 201000010099 disease Diseases 0.000 claims description 62
• 230000005764 inhibitory process Effects 0.000 claims description 56
• 101150040459 RAS gene Proteins 0.000 claims description 54
• 101150076031 RAS1 gene Proteins 0.000 claims description 54
• 239000003112 inhibitor Substances 0.000 claims description 46
• 239000003814 drug Substances 0.000 claims description 43
• 102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 claims description 42
• 230000004913 activation Effects 0.000 claims description 42
• 101100523539 Mus musculus Raf1 gene Proteins 0.000 claims description 40
• 229940079593 drug Drugs 0.000 claims description 39
• 102000043136 MAP kinase family Human genes 0.000 claims description 37
• 108091054455 MAP kinase family Proteins 0.000 claims description 36
• 238000009472 formulation Methods 0.000 claims description 36
• ARRNBPCNZJXHRJ-UHFFFAOYSA-M hydron;tetrabutylazanium;phosphate Chemical compound OP(O)([O-])=O.CCCC[N+](CCCC)(CCCC)CCCC ARRNBPCNZJXHRJ-UHFFFAOYSA-M 0.000 claims description 33
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 31
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 31
• 238000004519 manufacturing process Methods 0.000 claims description 31
• BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 claims description 22
• 208000006673 asthma Diseases 0.000 claims description 21
• 229960002465 dabrafenib Drugs 0.000 claims description 20
• 206010035226 Plasma cell myeloma Diseases 0.000 claims description 19
• 206010009944 Colon cancer Diseases 0.000 claims description 18
• 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 17
• 150000003839 salts Chemical class 0.000 claims description 17
• 230000001684 chronic effect Effects 0.000 claims description 16
• 239000002131 composite material Substances 0.000 claims description 16
• 208000027866 inflammatory disease Diseases 0.000 claims description 16
• 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims description 16
• 208000011231 Crohn disease Diseases 0.000 claims description 15
• 201000008808 Fibrosarcoma Diseases 0.000 claims description 14
• 201000004681 Psoriasis Diseases 0.000 claims description 13
• 230000002238 attenuated effect Effects 0.000 claims description 13
• 238000000338 in vitro Methods 0.000 claims description 13
• 230000002401 inhibitory effect Effects 0.000 claims description 13
• 201000009030 Carcinoma Diseases 0.000 claims description 12
• 208000034578 Multiple myelomas Diseases 0.000 claims description 12
• 206010033128 Ovarian cancer Diseases 0.000 claims description 12
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 11
• 201000010989 colorectal carcinoma Diseases 0.000 claims description 11
• 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims description 11
• 230000001394 metastastic effect Effects 0.000 claims description 11
• 206010061289 metastatic neoplasm Diseases 0.000 claims description 11
• 230000001850 reproductive effect Effects 0.000 claims description 11
• 229920006395 saturated elastomer Polymers 0.000 claims description 11
• 206010003571 Astrocytoma Diseases 0.000 claims description 10
• 206010009900 Colitis ulcerative Diseases 0.000 claims description 10
• 241001465754 Metazoa Species 0.000 claims description 10
• 208000000453 Skin Neoplasms Diseases 0.000 claims description 10
• 201000006704 Ulcerative Colitis Diseases 0.000 claims description 10
• 206010046851 Uveitis Diseases 0.000 claims description 10
• 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 10
• 229940124647 MEK inhibitor Drugs 0.000 claims description 9
• 206010052779 Transplant rejections Diseases 0.000 claims description 9
• 206010064930 age-related macular degeneration Diseases 0.000 claims description 9
• 201000005667 central retinal vein occlusion Diseases 0.000 claims description 9
• 239000003085 diluting agent Substances 0.000 claims description 9
• 150000004677 hydrates Chemical class 0.000 claims description 9
• 230000035755 proliferation Effects 0.000 claims description 9
• 208000004644 retinal vein occlusion Diseases 0.000 claims description 9
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 9
• GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 claims description 9
• 206010012688 Diabetic retinal oedema Diseases 0.000 claims description 8
• 206010012689 Diabetic retinopathy Diseases 0.000 claims description 8
• 208000024770 Thyroid neoplasm Diseases 0.000 claims description 8
• 230000033228 biological regulation Effects 0.000 claims description 8
• 102000006495 integrins Human genes 0.000 claims description 8
• 108010044426 integrins Proteins 0.000 claims description 8
• 201000000849 skin cancer Diseases 0.000 claims description 8
• LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 claims description 8
• 201000003883 Cystic fibrosis Diseases 0.000 claims description 7
• 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 7
• 206010013774 Dry eye Diseases 0.000 claims description 7
• 208000000208 Wet Macular Degeneration Diseases 0.000 claims description 7
• 206010006451 bronchitis Diseases 0.000 claims description 7
• 201000000050 myeloid neoplasm Diseases 0.000 claims description 7
• 230000000414 obstructive effect Effects 0.000 claims description 7
• 201000002510 thyroid cancer Diseases 0.000 claims description 7
• 229960004066 trametinib Drugs 0.000 claims description 7
• 229960003862 vemurafenib Drugs 0.000 claims description 7
• 206010006458 Bronchitis chronic Diseases 0.000 claims description 6
• 206010010744 Conjunctivitis allergic Diseases 0.000 claims description 6
• 206010012442 Dermatitis contact Diseases 0.000 claims description 6
• 206010061535 Ovarian neoplasm Diseases 0.000 claims description 6
• 206010033701 Papillary thyroid cancer Diseases 0.000 claims description 6
• 208000009956 adenocarcinoma Diseases 0.000 claims description 6
• 208000002205 allergic conjunctivitis Diseases 0.000 claims description 6
• 208000024998 atopic conjunctivitis Diseases 0.000 claims description 6
• 201000008937 atopic dermatitis Diseases 0.000 claims description 6
• 208000007451 chronic bronchitis Diseases 0.000 claims description 6
• 210000000496 pancreas Anatomy 0.000 claims description 6
• 230000004224 protection Effects 0.000 claims description 6
• CYOHGALHFOKKQC-UHFFFAOYSA-N selumetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1Cl CYOHGALHFOKKQC-UHFFFAOYSA-N 0.000 claims description 6
• 208000030045 thyroid gland papillary carcinoma Diseases 0.000 claims description 6
• 208000015943 Coeliac disease Diseases 0.000 claims description 5
• 206010010741 Conjunctivitis Diseases 0.000 claims description 5
• 206010014561 Emphysema Diseases 0.000 claims description 5
• 208000019693 Lung disease Diseases 0.000 claims description 5
• 125000000217 alkyl group Chemical group 0.000 claims description 5
• 208000010668 atopic eczema Diseases 0.000 claims description 5
• 208000006990 cholangiocarcinoma Diseases 0.000 claims description 5
• 229960002271 cobimetinib Drugs 0.000 claims description 5
• 208000010247 contact dermatitis Diseases 0.000 claims description 5
• 201000011190 diabetic macular edema Diseases 0.000 claims description 5
• 230000003511 endothelial effect Effects 0.000 claims description 5
• 229960005386 ipilimumab Drugs 0.000 claims description 5
• 208000002780 macular degeneration Diseases 0.000 claims description 5
• 208000023356 medullary thyroid gland carcinoma Diseases 0.000 claims description 5
• 230000002980 postoperative effect Effects 0.000 claims description 5
• 206010039083 rhinitis Diseases 0.000 claims description 5
• 229950010746 selumetinib Drugs 0.000 claims description 5
• 206010052747 Adenocarcinoma pancreas Diseases 0.000 claims description 4
• 208000002177 Cataract Diseases 0.000 claims description 4
• 206010012438 Dermatitis atopic Diseases 0.000 claims description 4
• 206010016935 Follicular thyroid cancer Diseases 0.000 claims description 4
• 208000010412 Glaucoma Diseases 0.000 claims description 4
• 206010020772 Hypertension Diseases 0.000 claims description 4
• 206010025415 Macular oedema Diseases 0.000 claims description 4
• 208000007054 Medullary Carcinoma Diseases 0.000 claims description 4
• 108010029485 Protein Isoforms Proteins 0.000 claims description 4
• 102000001708 Protein Isoforms Human genes 0.000 claims description 4
• 230000000259 anti-tumor effect Effects 0.000 claims description 4
• 229960000397 bevacizumab Drugs 0.000 claims description 4
• 208000011325 dry age related macular degeneration Diseases 0.000 claims description 4
• 230000003325 follicular Effects 0.000 claims description 4
• 201000009277 hairy cell leukemia Diseases 0.000 claims description 4
• 201000010230 macular retinal edema Diseases 0.000 claims description 4
• 238000002156 mixing Methods 0.000 claims description 4
• 201000002094 pancreatic adenocarcinoma Diseases 0.000 claims description 4
• 201000009890 sinusitis Diseases 0.000 claims description 4
• 208000030901 thyroid gland follicular carcinoma Diseases 0.000 claims description 4
• 201000004066 Ganglioglioma Diseases 0.000 claims description 3
• 150000001204 N-oxides Chemical class 0.000 claims description 3
• 201000007288 Pleomorphic xanthoastrocytoma Diseases 0.000 claims description 3
• 238000002512 chemotherapy Methods 0.000 claims description 3
• RESIMIUSNACMNW-BXRWSSRYSA-N cobimetinib fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F RESIMIUSNACMNW-BXRWSSRYSA-N 0.000 claims description 3
• 206010012601 diabetes mellitus Diseases 0.000 claims description 3
• 238000005516 engineering process Methods 0.000 claims description 3
• 125000001188 haloalkyl group Chemical group 0.000 claims description 3
• 230000002779 inactivation Effects 0.000 claims description 3
• 206010023332 keratitis Diseases 0.000 claims description 3
• 201000010666 keratoconjunctivitis Diseases 0.000 claims description 3
• 239000003550 marker Substances 0.000 claims description 3
• 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 claims description 3
• 201000003651 pulmonary sarcoidosis Diseases 0.000 claims description 3
• 201000000306 sarcoidosis Diseases 0.000 claims description 3
• 201000004624 Dermatitis Diseases 0.000 claims description 2
• 206010064212 Eosinophilic oesophagitis Diseases 0.000 claims description 2
• 208000009329 Graft vs Host Disease Diseases 0.000 claims description 2
• 125000003545 alkoxy group Chemical group 0.000 claims description 2
• 230000000172 allergic effect Effects 0.000 claims description 2
• 201000000708 eosinophilic esophagitis Diseases 0.000 claims description 2
• 125000003709 fluoroalkyl group Chemical group 0.000 claims description 2
• 208000024908 graft versus host disease Diseases 0.000 claims description 2
• 125000004438 haloalkoxy group Chemical group 0.000 claims description 2
• 230000000968 intestinal effect Effects 0.000 claims description 2
• 229950002104 ontuxizumab Drugs 0.000 claims description 2
• 230000002611 ovarian Effects 0.000 claims description 2
• 230000001681 protective effect Effects 0.000 claims description 2
• 230000002685 pulmonary effect Effects 0.000 claims description 2
• 238000011255 standard chemotherapy Methods 0.000 claims description 2
• 102000008096 B7-H1 Antigen Human genes 0.000 claims 2
• 108010074708 B7-H1 Antigen Proteins 0.000 claims 2
• 108090000288 Glycoproteins Proteins 0.000 claims 2
• 102000003886 Glycoproteins Human genes 0.000 claims 2
• 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 2
• 201000007286 Pilocytic astrocytoma Diseases 0.000 claims 2
• IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 claims 2
• 229950009791 durvalumab Drugs 0.000 claims 2
• 208000036971 interstitial lung disease 2 Diseases 0.000 claims 2
• 229960003301 nivolumab Drugs 0.000 claims 2
• 229960002621 pembrolizumab Drugs 0.000 claims 2
• 239000012453 solvate Substances 0.000 claims 2
• 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims 1
• 102000008203 CTLA-4 Antigen Human genes 0.000 claims 1
• 108010021064 CTLA-4 Antigen Proteins 0.000 claims 1
• 229940045513 CTLA4 antagonist Drugs 0.000 claims 1
• 206010011715 Cyclitis Diseases 0.000 claims 1
• 241000196324 Embryophyta Species 0.000 claims 1
• 208000008069 Geographic Atrophy Diseases 0.000 claims 1
• 102100037850 Interferon gamma Human genes 0.000 claims 1
• 108010074328 Interferon-gamma Proteins 0.000 claims 1
• 206010022941 Iridocyclitis Diseases 0.000 claims 1
• 208000009319 Keratoconjunctivitis Sicca Diseases 0.000 claims 1
• 208000004788 Pars Planitis Diseases 0.000 claims 1
• 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 1
• 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 1
• 201000004612 anterior uveitis Diseases 0.000 claims 1
• 229960003270 belimumab Drugs 0.000 claims 1
• 206010009887 colitis Diseases 0.000 claims 1
• 230000002327 eosinophilic effect Effects 0.000 claims 1
• 125000001153 fluoro group Chemical group F* 0.000 claims 1
• 230000001900 immune effect Effects 0.000 claims 1
• 229950001014 intetumumab Drugs 0.000 claims 1
• 210000002850 nasal mucosa Anatomy 0.000 claims 1
• 239000008194 pharmaceutical composition Substances 0.000 abstract description 12
• 210000004027 cell Anatomy 0.000 description 153
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 60
• 230000000694 effects Effects 0.000 description 53
• 238000002474 experimental method Methods 0.000 description 43
• 108090000623 proteins and genes Proteins 0.000 description 42
• 239000000243 solution Substances 0.000 description 35
• 230000015572 biosynthetic process Effects 0.000 description 31
• 230000033115 angiogenesis Effects 0.000 description 30
• 210000001508 eye Anatomy 0.000 description 30
• 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 29
• 235000018102 proteins Nutrition 0.000 description 29
• 102000004169 proteins and genes Human genes 0.000 description 29
• 230000011664 signaling Effects 0.000 description 29
• 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 description 25
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 25
• 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 description 24
• 238000006243 chemical reaction Methods 0.000 description 24
• 238000003786 synthesis reaction Methods 0.000 description 24
• 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 23
• PQLFROTZSIMBKR-UHFFFAOYSA-N ethenyl carbonochloridate Chemical compound ClC(=O)OC=C PQLFROTZSIMBKR-UHFFFAOYSA-N 0.000 description 23
• 230000002018 overexpression Effects 0.000 description 23
• 108091000080 Phosphotransferase Proteins 0.000 description 22
• 230000014509 gene expression Effects 0.000 description 22
• 102000020233 phosphotransferase Human genes 0.000 description 22
• 102000027426 receptor tyrosine kinases Human genes 0.000 description 22
• 210000001519 tissue Anatomy 0.000 description 22
• 230000004663 cell proliferation Effects 0.000 description 21
• 108091008598 receptor tyrosine kinases Proteins 0.000 description 21
• IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 20
• 208000002193 Pain Diseases 0.000 description 20
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 20
• 230000007246 mechanism Effects 0.000 description 20
• 239000007787 solid Substances 0.000 description 20
• 230000006870 function Effects 0.000 description 19
• 102000005962 receptors Human genes 0.000 description 19
• 108020003175 receptors Proteins 0.000 description 19
• 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 18
• 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 18
• 239000003795 chemical substances by application Substances 0.000 description 18
• 238000010586 diagram Methods 0.000 description 17
• 238000001727 in vivo Methods 0.000 description 17
• 208000011580 syndromic disease Diseases 0.000 description 17
• 238000012360 testing method Methods 0.000 description 17
• IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 16
• 239000003921 oil Substances 0.000 description 16
• 230000019491 signal transduction Effects 0.000 description 16
• 108091008605 VEGF receptors Proteins 0.000 description 15
• 239000007788 liquid Substances 0.000 description 15
• 230000036407 pain Effects 0.000 description 15
• 238000012545 processing Methods 0.000 description 15
• 239000000543 intermediate Substances 0.000 description 14
• 238000000746 purification Methods 0.000 description 14
• 230000004044 response Effects 0.000 description 14
• 206010039073 rheumatoid arthritis Diseases 0.000 description 14
• 201000001320 Atherosclerosis Diseases 0.000 description 13
• 108010009202 Growth Factor Receptors Proteins 0.000 description 13
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 13
• 241000700605 Viruses Species 0.000 description 13
• 206010003246 arthritis Diseases 0.000 description 13
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 13
• 239000000463 material Substances 0.000 description 13
• 235000019198 oils Nutrition 0.000 description 13
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 13
• 230000000306 recurrent effect Effects 0.000 description 13
• 230000001105 regulatory effect Effects 0.000 description 13
• 102000001301 EGF receptor Human genes 0.000 description 12
• 108060006698 EGF receptor Proteins 0.000 description 12
• 102000009465 Growth Factor Receptors Human genes 0.000 description 12
• CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 12
• 230000001154 acute effect Effects 0.000 description 12
• 230000012010 growth Effects 0.000 description 12
• 102000018233 Fibroblast Growth Factor Human genes 0.000 description 11
• 108050007372 Fibroblast Growth Factor Proteins 0.000 description 11
• 206010016654 Fibrosis Diseases 0.000 description 11
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 11
• 102100040247 Tumor necrosis factor Human genes 0.000 description 11
• 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 11
• 239000007853 buffer solution Substances 0.000 description 11
• 239000004202 carbamide Substances 0.000 description 11
• 235000013877 carbamide Nutrition 0.000 description 11
• 125000000524 functional group Chemical group 0.000 description 11
• 239000003446 ligand Substances 0.000 description 11
• 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 11
• 108010014186 ras Proteins Proteins 0.000 description 11
• 210000003491 skin Anatomy 0.000 description 11
• 239000000126 substance Substances 0.000 description 11
• 239000000725 suspension Substances 0.000 description 11
• 239000003826 tablet Substances 0.000 description 11
• BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 description 10
• 102100039788 GTPase NRas Human genes 0.000 description 10
• 101000744505 Homo sapiens GTPase NRas Proteins 0.000 description 10
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 10
• 210000004369 blood Anatomy 0.000 description 10
• 239000008280 blood Substances 0.000 description 10
• 150000002148 esters Chemical class 0.000 description 10
• 230000002757 inflammatory effect Effects 0.000 description 10
• 208000004296 neuralgia Diseases 0.000 description 10
• 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 10
• 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 10
• 238000011160 research Methods 0.000 description 10
• 239000002904 solvent Substances 0.000 description 10
• 238000005406 washing Methods 0.000 description 10
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 9
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 9
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
• 208000027418 Wounds and injury Diseases 0.000 description 9
• 239000003995 emulsifying agent Substances 0.000 description 9
• 229940126864 fibroblast growth factor Drugs 0.000 description 9
• 230000004761 fibrosis Effects 0.000 description 9
• 238000011534 incubation Methods 0.000 description 9
• 210000004072 lung Anatomy 0.000 description 9
• 208000021722 neuropathic pain Diseases 0.000 description 9
• 102000004127 Cytokines Human genes 0.000 description 8
• 238000005481 NMR spectroscopy Methods 0.000 description 8
• 102000038012 SFKs Human genes 0.000 description 8
• 108091008118 SFKs Proteins 0.000 description 8
• 102000001332 SRC Human genes 0.000 description 8
• 206010039491 Sarcoma Diseases 0.000 description 8
• 206010052428 Wound Diseases 0.000 description 8
• 150000001412 amines Chemical class 0.000 description 8
• 239000000969 carrier Substances 0.000 description 8
• 230000001413 cellular effect Effects 0.000 description 8
• 210000002889 endothelial cell Anatomy 0.000 description 8
• 239000002158 endotoxin Substances 0.000 description 8
• 239000002609 medium Substances 0.000 description 8
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 8
• 210000000056 organ Anatomy 0.000 description 8
• 229920000371 poly(diallyldimethylammonium chloride) polymer Polymers 0.000 description 8
• 239000000843 powder Substances 0.000 description 8
• 239000011541 reaction mixture Substances 0.000 description 8
• 238000006467 substitution reaction Methods 0.000 description 8
• 230000004083 survival effect Effects 0.000 description 8
• 238000005160 1H NMR spectroscopy Methods 0.000 description 7
• 108090000695 Cytokines Proteins 0.000 description 7
• 102100030708 GTPase KRas Human genes 0.000 description 7
• 101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 7
• 206010027476 Metastases Diseases 0.000 description 7
• 102000038030 PI3Ks Human genes 0.000 description 7
• 108091007960 PI3Ks Proteins 0.000 description 7
• 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 7
• 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 7
• 241000700159 Rattus Species 0.000 description 7
• 235000015076 Shorea robusta Nutrition 0.000 description 7
• 230000002159 abnormal effect Effects 0.000 description 7
• 239000002253 acid Substances 0.000 description 7
• 230000003213 activating effect Effects 0.000 description 7
• 239000000853 adhesive Substances 0.000 description 7
• 230000001070 adhesive effect Effects 0.000 description 7
• 230000010261 cell growth Effects 0.000 description 7
• 239000000356 contaminant Substances 0.000 description 7
• 239000003925 fat Substances 0.000 description 7
• 235000019197 fats Nutrition 0.000 description 7
• 238000001914 filtration Methods 0.000 description 7
• 239000003102 growth factor Substances 0.000 description 7
• 230000007062 hydrolysis Effects 0.000 description 7
• 238000006460 hydrolysis reaction Methods 0.000 description 7
• 208000032839 leukemia Diseases 0.000 description 7
• 229920006008 lipopolysaccharide Polymers 0.000 description 7
• 210000004698 lymphocyte Anatomy 0.000 description 7
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
• 239000012044 organic layer Substances 0.000 description 7
• 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 7
• 239000000546 pharmaceutical excipient Substances 0.000 description 7
• 238000002360 preparation method Methods 0.000 description 7
• 238000003672 processing method Methods 0.000 description 7
• 239000000047 product Substances 0.000 description 7
• 102000009929 raf Kinases Human genes 0.000 description 7
• 108010077182 raf Kinases Proteins 0.000 description 7
• RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 7
• 230000003827 upregulation Effects 0.000 description 7
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
• 241000725303 Human immunodeficiency virus Species 0.000 description 6
• 206010061902 Pancreatic neoplasm Diseases 0.000 description 6
• 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 6
• 206010060862 Prostate cancer Diseases 0.000 description 6
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 6
• 102000001253 Protein Kinase Human genes 0.000 description 6
• 108010091528 Proto-Oncogene Proteins B-raf Proteins 0.000 description 6
• 208000025747 Rheumatic disease Diseases 0.000 description 6
• 206010040070 Septic Shock Diseases 0.000 description 6
• 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 6
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
• 230000006907 apoptotic process Effects 0.000 description 6
• 239000002585 base Substances 0.000 description 6
• 239000000090 biomarker Substances 0.000 description 6
• 210000004204 blood vessel Anatomy 0.000 description 6
• 210000000988 bone and bone Anatomy 0.000 description 6
• 239000012267 brine Substances 0.000 description 6
• 239000000872 buffer Substances 0.000 description 6
• 239000003153 chemical reaction reagent Substances 0.000 description 6
• 239000006071 cream Substances 0.000 description 6
• 230000001419 dependent effect Effects 0.000 description 6
• 238000010790 dilution Methods 0.000 description 6
• 239000012895 dilution Substances 0.000 description 6
• 239000001963 growth medium Substances 0.000 description 6
• 238000004128 high performance liquid chromatography Methods 0.000 description 6
• 210000004185 liver Anatomy 0.000 description 6
• 229910052943 magnesium sulfate Inorganic materials 0.000 description 6
• 235000019341 magnesium sulphate Nutrition 0.000 description 6
• 230000036210 malignancy Effects 0.000 description 6
• 230000003211 malignant effect Effects 0.000 description 6
• 230000001404 mediated effect Effects 0.000 description 6
• 230000009401 metastasis Effects 0.000 description 6
• 210000000214 mouth Anatomy 0.000 description 6
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
• 208000008443 pancreatic carcinoma Diseases 0.000 description 6
• 230000026731 phosphorylation Effects 0.000 description 6
• 238000006366 phosphorylation reaction Methods 0.000 description 6
• 210000002307 prostate Anatomy 0.000 description 6
• 108060006633 protein kinase Proteins 0.000 description 6
• 239000000523 sample Substances 0.000 description 6
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
• 206010041823 squamous cell carcinoma Diseases 0.000 description 6
• 238000003756 stirring Methods 0.000 description 6
• 230000008685 targeting Effects 0.000 description 6
• 206010006187 Breast cancer Diseases 0.000 description 5
• 208000026310 Breast neoplasm Diseases 0.000 description 5
• 241000282693 Cercopithecidae Species 0.000 description 5
• 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 description 5
• 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 description 5
• 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 description 5
• 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 description 5
• 102000016621 Focal Adhesion Protein-Tyrosine Kinases Human genes 0.000 description 5
• 108010067715 Focal Adhesion Protein-Tyrosine Kinases Proteins 0.000 description 5
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 5
• 102100029974 GTPase HRas Human genes 0.000 description 5
• 208000032612 Glial tumor Diseases 0.000 description 5
• 206010018338 Glioma Diseases 0.000 description 5
• 206010018364 Glomerulonephritis Diseases 0.000 description 5
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
• 101000584633 Homo sapiens GTPase HRas Proteins 0.000 description 5
• 241000699666 Mus <mouse, genus> Species 0.000 description 5
• 206010029260 Neuroblastoma Diseases 0.000 description 5
• 108700020796 Oncogene Proteins 0.000 description 5
• 241000283973 Oryctolagus cuniculus Species 0.000 description 5
• YZDJQTHVDDOVHR-UHFFFAOYSA-N PLX-4720 Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(Cl)=CN=C3NC=2)=C1F YZDJQTHVDDOVHR-UHFFFAOYSA-N 0.000 description 5
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 5
• WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 5
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
• 208000006011 Stroke Diseases 0.000 description 5
• 230000005856 abnormality Effects 0.000 description 5
• 235000015107 ale Nutrition 0.000 description 5
• 210000004556 brain Anatomy 0.000 description 5
• 239000002775 capsule Substances 0.000 description 5
• 150000004657 carbamic acid derivatives Chemical class 0.000 description 5
• 150000001732 carboxylic acid derivatives Chemical class 0.000 description 5
• 150000001768 cations Chemical class 0.000 description 5
• 239000012141 concentrate Substances 0.000 description 5
• 210000002808 connective tissue Anatomy 0.000 description 5
• 231100000433 cytotoxic Toxicity 0.000 description 5
• 230000001472 cytotoxic effect Effects 0.000 description 5
• 238000011161 development Methods 0.000 description 5
• 230000018109 developmental process Effects 0.000 description 5
• 239000003937 drug carrier Substances 0.000 description 5
• 239000012636 effector Substances 0.000 description 5
• 230000004927 fusion Effects 0.000 description 5
• 239000004615 ingredient Substances 0.000 description 5
• 201000005992 juvenile myelomonocytic leukemia Diseases 0.000 description 5
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 5
• 231100000590 oncogenic Toxicity 0.000 description 5
• 230000002246 oncogenic effect Effects 0.000 description 5
• 210000001672 ovary Anatomy 0.000 description 5
• 201000002528 pancreatic cancer Diseases 0.000 description 5
• AHWALFGBDFAJAI-UHFFFAOYSA-N phenyl carbonochloridate Chemical compound ClC(=O)OC1=CC=CC=C1 AHWALFGBDFAJAI-UHFFFAOYSA-N 0.000 description 5
• 230000003389 potentiating effect Effects 0.000 description 5
• 230000008569 process Effects 0.000 description 5
• 239000000651 prodrug Substances 0.000 description 5
• 229940002612 prodrug Drugs 0.000 description 5
• 108700042226 ras Genes Proteins 0.000 description 5
• 201000009410 rhabdomyosarcoma Diseases 0.000 description 5
• 102200055464 rs113488022 Human genes 0.000 description 5
• 230000036303 septic shock Effects 0.000 description 5
• 235000017557 sodium bicarbonate Nutrition 0.000 description 5
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
• 239000000829 suppository Substances 0.000 description 5
• 230000009885 systemic effect Effects 0.000 description 5
• 238000002560 therapeutic procedure Methods 0.000 description 5
• 230000002792 vascular Effects 0.000 description 5
• 239000003981 vehicle Substances 0.000 description 5
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
• KOPFEFZSAMLEHK-UHFFFAOYSA-N 1h-pyrazole-5-carboxylic acid Chemical class OC(=O)C=1C=CNN=1 KOPFEFZSAMLEHK-UHFFFAOYSA-N 0.000 description 4
• RQRWZFJMPKHYIC-UHFFFAOYSA-N 5-tert-butyl-1h-pyrazole-3-carboxylic acid Chemical compound CC(C)(C)C1=CC(C(O)=O)=NN1 RQRWZFJMPKHYIC-UHFFFAOYSA-N 0.000 description 4
• 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 4
• 102100022014 Angiopoietin-1 receptor Human genes 0.000 description 4
• XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
• 229940125431 BRAF inhibitor Drugs 0.000 description 4
• ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 description 4
• 206010008342 Cervix carcinoma Diseases 0.000 description 4
• 208000000094 Chronic Pain Diseases 0.000 description 4
• ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 4
• 206010014759 Endometrial neoplasm Diseases 0.000 description 4
• 108091008794 FGF receptors Proteins 0.000 description 4
• 101000753291 Homo sapiens Angiopoietin-1 receptor Proteins 0.000 description 4
• 101000771237 Homo sapiens Serine/threonine-protein kinase A-Raf Proteins 0.000 description 4
• 241000701044 Human gammaherpesvirus 4 Species 0.000 description 4
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
• 239000002067 L01XE06 - Dasatinib Substances 0.000 description 4
• 230000005723 MEK inhibition Effects 0.000 description 4
• 201000003793 Myelodysplastic syndrome Diseases 0.000 description 4
• 208000009905 Neurofibromatoses Diseases 0.000 description 4
• 102000018471 Proto-Oncogene Proteins B-raf Human genes 0.000 description 4
• 102100029437 Serine/threonine-protein kinase A-Raf Human genes 0.000 description 4
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 4
• 201000005969 Uveal melanoma Diseases 0.000 description 4
• 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 4
• 238000002835 absorbance Methods 0.000 description 4
• QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
• 239000000443 aerosol Substances 0.000 description 4
• 208000026935 allergic disease Diseases 0.000 description 4
• 238000004458 analytical method Methods 0.000 description 4
• 210000001367 artery Anatomy 0.000 description 4
• 230000003143 atherosclerotic effect Effects 0.000 description 4
• 230000008901 benefit Effects 0.000 description 4
• 210000000170 cell membrane Anatomy 0.000 description 4
• 201000010881 cervical cancer Diseases 0.000 description 4
• 208000019425 cirrhosis of liver Diseases 0.000 description 4
• 229960002448 dasatinib Drugs 0.000 description 4
• 230000007812 deficiency Effects 0.000 description 4
• 230000004069 differentiation Effects 0.000 description 4
• 230000002496 gastric effect Effects 0.000 description 4
• 239000000499 gel Substances 0.000 description 4
• 235000011187 glycerol Nutrition 0.000 description 4
• HHLFWLYXYJOTON-UHFFFAOYSA-N glyoxylic acid Chemical compound OC(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-N 0.000 description 4
• 230000035876 healing Effects 0.000 description 4
• 206010073071 hepatocellular carcinoma Diseases 0.000 description 4
• 231100000844 hepatocellular carcinoma Toxicity 0.000 description 4
• 230000001965 increasing effect Effects 0.000 description 4
• 208000015181 infectious disease Diseases 0.000 description 4
• 239000007924 injection Substances 0.000 description 4
• 238000002347 injection Methods 0.000 description 4
• 230000002452 interceptive effect Effects 0.000 description 4
• 230000003834 intracellular effect Effects 0.000 description 4
• 238000001990 intravenous administration Methods 0.000 description 4
• 239000006210 lotion Substances 0.000 description 4
• 230000004770 neurodegeneration Effects 0.000 description 4
• 201000004931 neurofibromatosis Diseases 0.000 description 4
• 210000001331 nose Anatomy 0.000 description 4
• 239000002773 nucleotide Substances 0.000 description 4
• 239000002674 ointment Substances 0.000 description 4
• 201000008968 osteosarcoma Diseases 0.000 description 4
• OVLXOTUWFLHWQT-UHFFFAOYSA-N oxazolo[4,5-b]pyridin-2(3H)-one Chemical compound C1=CC=C2OC(=O)NC2=N1 OVLXOTUWFLHWQT-UHFFFAOYSA-N 0.000 description 4
• 239000003755 preservative agent Substances 0.000 description 4
• 125000004076 pyridyl group Chemical group 0.000 description 4
• 210000000664 rectum Anatomy 0.000 description 4
• 238000012552 review Methods 0.000 description 4
• 102000009076 src-Family Kinases Human genes 0.000 description 4
• 108010087686 src-Family Kinases Proteins 0.000 description 4
• 238000010186 staining Methods 0.000 description 4
• 238000001356 surgical procedure Methods 0.000 description 4
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
• 238000013518 transcription Methods 0.000 description 4
• 230000035897 transcription Effects 0.000 description 4
• 210000004881 tumor cell Anatomy 0.000 description 4
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 4
• 208000008662 verrucous carcinoma Diseases 0.000 description 4
• CGOZYYXGKRKZRR-UHFFFAOYSA-N 5-tert-butyl-2-(3-fluorophenyl)pyrazole-3-carboxylic acid Chemical compound N1=C(C(C)(C)C)C=C(C(O)=O)N1C1=CC=CC(F)=C1 CGOZYYXGKRKZRR-UHFFFAOYSA-N 0.000 description 3
• 208000031261 Acute myeloid leukaemia Diseases 0.000 description 3
• 229920000936 Agarose Polymers 0.000 description 3
• 208000024827 Alzheimer disease Diseases 0.000 description 3
• 102000009840 Angiopoietins Human genes 0.000 description 3
• 108010009906 Angiopoietins Proteins 0.000 description 3
• 201000003076 Angiosarcoma Diseases 0.000 description 3
• 206010003210 Arteriosclerosis Diseases 0.000 description 3
• 201000006474 Brain Ischemia Diseases 0.000 description 3
• 206010008120 Cerebral ischaemia Diseases 0.000 description 3
• 108020004705 Codon Proteins 0.000 description 3
• 102000008186 Collagen Human genes 0.000 description 3
• 108010035532 Collagen Proteins 0.000 description 3
• XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 3
• 101100481408 Danio rerio tie2 gene Proteins 0.000 description 3
• 206010014733 Endometrial cancer Diseases 0.000 description 3
• 102000004190 Enzymes Human genes 0.000 description 3
• 108090000790 Enzymes Proteins 0.000 description 3
• 208000025127 Erdheim-Chester disease Diseases 0.000 description 3
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
• LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
• 208000009386 Experimental Arthritis Diseases 0.000 description 3
• 102100028138 F-box/WD repeat-containing protein 7 Human genes 0.000 description 3
• 206010019280 Heart failures Diseases 0.000 description 3
• 208000001258 Hemangiosarcoma Diseases 0.000 description 3
• 102100021866 Hepatocyte growth factor Human genes 0.000 description 3
• 208000017604 Hodgkin disease Diseases 0.000 description 3
• 208000021519 Hodgkin lymphoma Diseases 0.000 description 3
• 208000010747 Hodgkins lymphoma Diseases 0.000 description 3
• 101001060231 Homo sapiens F-box/WD repeat-containing protein 7 Proteins 0.000 description 3
• 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 3
• 241001502974 Human gammaherpesvirus 8 Species 0.000 description 3
• 241000701806 Human papillomavirus Species 0.000 description 3
• 206010020751 Hypersensitivity Diseases 0.000 description 3
• 206010065390 Inflammatory pain Diseases 0.000 description 3
• 208000007766 Kaposi sarcoma Diseases 0.000 description 3
• 208000018142 Leiomyosarcoma Diseases 0.000 description 3
• 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
• 240000007472 Leucaena leucocephala Species 0.000 description 3
• WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
• 206010025323 Lymphomas Diseases 0.000 description 3
• 241000124008 Mammalia Species 0.000 description 3
• 101100481410 Mus musculus Tek gene Proteins 0.000 description 3
• 241000699670 Mus sp. Species 0.000 description 3
• 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 3
• 206010028851 Necrosis Diseases 0.000 description 3
• 206010029240 Neuritis Diseases 0.000 description 3
• 208000008589 Obesity Diseases 0.000 description 3
• 208000001132 Osteoporosis Diseases 0.000 description 3
• 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 3
• 229910019142 PO4 Inorganic materials 0.000 description 3
• 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 3
• 102100033237 Pro-epidermal growth factor Human genes 0.000 description 3
• 101710141955 RAF proto-oncogene serine/threonine-protein kinase Proteins 0.000 description 3
• 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 3
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
• 208000021712 Soft tissue sarcoma Diseases 0.000 description 3
• 208000005718 Stomach Neoplasms Diseases 0.000 description 3
• 108091023040 Transcription factor Proteins 0.000 description 3
• 102000040945 Transcription factor Human genes 0.000 description 3
• 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 3
• 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 description 3
• DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 3
• 150000001241 acetals Chemical class 0.000 description 3
• 239000012190 activator Substances 0.000 description 3
• 210000000577 adipose tissue Anatomy 0.000 description 3
• 208000007128 adrenocortical carcinoma Diseases 0.000 description 3
• 201000000028 adult respiratory distress syndrome Diseases 0.000 description 3
• 235000001014 amino acid Nutrition 0.000 description 3
• 229940121363 anti-inflammatory agent Drugs 0.000 description 3
• 239000002260 anti-inflammatory agent Substances 0.000 description 3
• 230000000840 anti-viral effect Effects 0.000 description 3
• 239000000427 antigen Substances 0.000 description 3
• 108091007433 antigens Proteins 0.000 description 3
• 102000036639 antigens Human genes 0.000 description 3
• 208000011775 arteriosclerosis disease Diseases 0.000 description 3
• 230000001174 ascending effect Effects 0.000 description 3
• 239000012298 atmosphere Substances 0.000 description 3
• 239000011324 bead Substances 0.000 description 3
• 210000003445 biliary tract Anatomy 0.000 description 3
• 230000000903 blocking effect Effects 0.000 description 3
• 210000000601 blood cell Anatomy 0.000 description 3
• 238000007664 blowing Methods 0.000 description 3
• 101150048834 braF gene Proteins 0.000 description 3
• 230000003139 buffering effect Effects 0.000 description 3
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
• 239000001768 carboxy methyl cellulose Substances 0.000 description 3
• 150000007942 carboxylates Chemical class 0.000 description 3
• 231100000504 carcinogenesis Toxicity 0.000 description 3
• 125000002091 cationic group Chemical group 0.000 description 3
• 230000020411 cell activation Effects 0.000 description 3
• 230000006369 cell cycle progression Effects 0.000 description 3
• 230000024245 cell differentiation Effects 0.000 description 3
• 239000006285 cell suspension Substances 0.000 description 3
• 238000005119 centrifugation Methods 0.000 description 3
• 206010008118 cerebral infarction Diseases 0.000 description 3
• 125000003636 chemical group Chemical group 0.000 description 3
• 229920001436 collagen Polymers 0.000 description 3
• 208000029742 colonic neoplasm Diseases 0.000 description 3
• 239000012230 colorless oil Substances 0.000 description 3
• 238000004440 column chromatography Methods 0.000 description 3
• 230000000052 comparative effect Effects 0.000 description 3
• 239000010949 copper Substances 0.000 description 3
• 125000004122 cyclic group Chemical group 0.000 description 3
• 230000001086 cytosolic effect Effects 0.000 description 3
• 239000000539 dimer Substances 0.000 description 3
• 231100000673 dose–response relationship Toxicity 0.000 description 3
• 238000001035 drying Methods 0.000 description 3
• 230000001804 emulsifying effect Effects 0.000 description 3
• 230000002124 endocrine Effects 0.000 description 3
• 201000003914 endometrial carcinoma Diseases 0.000 description 3
• 239000003623 enhancer Substances 0.000 description 3
• DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 3
• 239000012091 fetal bovine serum Substances 0.000 description 3
• 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 description 3
• 239000000796 flavoring agent Substances 0.000 description 3
• 201000006585 gastric adenocarcinoma Diseases 0.000 description 3
• 206010017758 gastric cancer Diseases 0.000 description 3
• 238000010914 gene-directed enzyme pro-drug therapy Methods 0.000 description 3
• 230000002068 genetic effect Effects 0.000 description 3
• 239000008187 granular material Substances 0.000 description 3
• UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 3
• 208000006454 hepatitis Diseases 0.000 description 3
• 231100000283 hepatitis Toxicity 0.000 description 3
• 230000003463 hyperproliferative effect Effects 0.000 description 3
• JXXWJMUPNZDILL-UHFFFAOYSA-N imidazo[4,5-b]pyridin-2-one Chemical compound C1=CC=NC2=NC(=O)N=C21 JXXWJMUPNZDILL-UHFFFAOYSA-N 0.000 description 3
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
• 230000006872 improvement Effects 0.000 description 3
• 230000028709 inflammatory response Effects 0.000 description 3
• 230000003993 interaction Effects 0.000 description 3
• 210000000936 intestine Anatomy 0.000 description 3
• 150000002513 isocyanates Chemical class 0.000 description 3
• 125000000468 ketone group Chemical group 0.000 description 3
• 210000003734 kidney Anatomy 0.000 description 3
• 239000007937 lozenge Substances 0.000 description 3
• 208000003747 lymphoid leukemia Diseases 0.000 description 3
• 210000002540 macrophage Anatomy 0.000 description 3
• 235000013336 milk Nutrition 0.000 description 3
• 239000008267 milk Substances 0.000 description 3
• 210000004080 milk Anatomy 0.000 description 3
• 210000001616 monocyte Anatomy 0.000 description 3
• 201000006417 multiple sclerosis Diseases 0.000 description 3
• 208000010125 myocardial infarction Diseases 0.000 description 3
• 230000017074 necrotic cell death Effects 0.000 description 3
• 208000015122 neurodegenerative disease Diseases 0.000 description 3
• 210000002569 neuron Anatomy 0.000 description 3
• 201000001119 neuropathy Diseases 0.000 description 3
• 230000007823 neuropathy Effects 0.000 description 3
• 235000020824 obesity Nutrition 0.000 description 3
• 230000002746 orthostatic effect Effects 0.000 description 3
• 230000011164 ossification Effects 0.000 description 3
• 201000008482 osteoarthritis Diseases 0.000 description 3
• 208000033808 peripheral neuropathy Diseases 0.000 description 3
• 230000002085 persistent effect Effects 0.000 description 3
• 239000012071 phase Substances 0.000 description 3
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
• 239000010452 phosphate Substances 0.000 description 3
• 102000004196 processed proteins & peptides Human genes 0.000 description 3
• 108090000765 processed proteins & peptides Proteins 0.000 description 3
• 208000005069 pulmonary fibrosis Diseases 0.000 description 3
• 230000009467 reduction Effects 0.000 description 3
• 230000002829 reductive effect Effects 0.000 description 3
• 208000037803 restenosis Diseases 0.000 description 3
• 230000000552 rheumatic effect Effects 0.000 description 3
• 230000037390 scarring Effects 0.000 description 3
• 230000035945 sensitivity Effects 0.000 description 3
• 239000000741 silica gel Substances 0.000 description 3
• 229910002027 silica gel Inorganic materials 0.000 description 3
• 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
• 239000003381 stabilizer Substances 0.000 description 3
• 201000011549 stomach cancer Diseases 0.000 description 3
• 239000000758 substrate Substances 0.000 description 3
• 208000024891 symptom Diseases 0.000 description 3
• FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 3
• 230000000699 topical effect Effects 0.000 description 3
• 230000002103 transcriptional effect Effects 0.000 description 3
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
• 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 3
• 241001529453 unidentified herpesvirus Species 0.000 description 3
• 230000006459 vascular development Effects 0.000 description 3
• DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 3
• PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
• YUXKOWPNKJSTPQ-AXWWPMSFSA-N (2s,3r)-2-amino-3-hydroxybutanoic acid;(2s)-2-amino-3-hydroxypropanoic acid Chemical compound OC[C@H](N)C(O)=O.C[C@@H](O)[C@H](N)C(O)=O YUXKOWPNKJSTPQ-AXWWPMSFSA-N 0.000 description 2
• VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 2
• MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
• 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
• OKNKZVLYAVPYHZ-UHFFFAOYSA-N 1-fluoro-1-phenylhydrazine;hydrochloride Chemical compound Cl.NN(F)C1=CC=CC=C1 OKNKZVLYAVPYHZ-UHFFFAOYSA-N 0.000 description 2
• VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
• KKVYYGGCHJGEFJ-UHFFFAOYSA-N 1-n-(4-chlorophenyl)-6-methyl-5-n-[3-(7h-purin-6-yl)pyridin-2-yl]isoquinoline-1,5-diamine Chemical compound N=1C=CC2=C(NC=3C(=CC=CN=3)C=3C=4N=CNC=4N=CN=3)C(C)=CC=C2C=1NC1=CC=C(Cl)C=C1 KKVYYGGCHJGEFJ-UHFFFAOYSA-N 0.000 description 2
• OJTBJKFKQSZLFG-UHFFFAOYSA-N 1h-pyrazole-5-carboxylic acid;hydrochloride Chemical compound Cl.OC(=O)C1=CC=NN1 OJTBJKFKQSZLFG-UHFFFAOYSA-N 0.000 description 2
• HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
• TYEYBOSBBBHJIV-UHFFFAOYSA-M 2-oxobutanoate Chemical compound CCC(=O)C([O-])=O TYEYBOSBBBHJIV-UHFFFAOYSA-M 0.000 description 2
• DIRINUVNYFAWQF-UHFFFAOYSA-N 4-chloro-3-nitropyridin-2-amine Chemical compound NC1=NC=CC(Cl)=C1[N+]([O-])=O DIRINUVNYFAWQF-UHFFFAOYSA-N 0.000 description 2
• IAVMYZXRASMAQF-UHFFFAOYSA-N 5-tert-butyl-2-(3-fluorophenyl)pyrazol-3-amine Chemical compound N1=C(C(C)(C)C)C=C(N)N1C1=CC=CC(F)=C1 IAVMYZXRASMAQF-UHFFFAOYSA-N 0.000 description 2
• WQUXJXDHYBIPCI-UHFFFAOYSA-N 5-tert-butyl-2-(3-methylphenyl)pyrazole-3-carboxylic acid Chemical compound C(C)(C)(C)C1=NN(C(=C1)C(=O)O)C1=CC(=CC=C1)C WQUXJXDHYBIPCI-UHFFFAOYSA-N 0.000 description 2
• 201000010028 Acrocephalosyndactylia Diseases 0.000 description 2
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
• 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
• QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
• 208000028185 Angioedema Diseases 0.000 description 2
• 241000416162 Astragalus gummifer Species 0.000 description 2
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
• 241000894006 Bacteria Species 0.000 description 2
• 206010005003 Bladder cancer Diseases 0.000 description 2
• 201000004569 Blindness Diseases 0.000 description 2
• 241001115070 Bornavirus Species 0.000 description 2
• 241000283690 Bos taurus Species 0.000 description 2
• 208000011691 Burkitt lymphomas Diseases 0.000 description 2
• 102100032912 CD44 antigen Human genes 0.000 description 2
• 206010006895 Cachexia Diseases 0.000 description 2
• KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
• 208000005623 Carcinogenesis Diseases 0.000 description 2
• 208000031229 Cardiomyopathies Diseases 0.000 description 2
• 108010078791 Carrier Proteins Proteins 0.000 description 2
• 102000000844 Cell Surface Receptors Human genes 0.000 description 2
• 108010001857 Cell Surface Receptors Proteins 0.000 description 2
• 108091006146 Channels Proteins 0.000 description 2
• 206010052358 Colorectal cancer metastatic Diseases 0.000 description 2
• RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
• 241001137251 Corvidae Species 0.000 description 2
• 241000709675 Coxsackievirus B3 Species 0.000 description 2
• 241000701022 Cytomegalovirus Species 0.000 description 2
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
• 108020004414 DNA Proteins 0.000 description 2
• 206010012434 Dermatitis allergic Diseases 0.000 description 2
• 208000002249 Diabetes Complications Diseases 0.000 description 2
• 208000032131 Diabetic Neuropathies Diseases 0.000 description 2
• 101100234002 Drosophila melanogaster Shal gene Proteins 0.000 description 2
• 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 description 2
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
• 238000002965 ELISA Methods 0.000 description 2
• 241000792859 Enema Species 0.000 description 2
• QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
• 241000282326 Felis catus Species 0.000 description 2
• 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 2
• 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
• 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 2
• 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 description 2
• 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 description 2
• 102000013446 GTP Phosphohydrolases Human genes 0.000 description 2
• 101710113436 GTPase KRas Proteins 0.000 description 2
• 108091006109 GTPases Proteins 0.000 description 2
• 208000018522 Gastrointestinal disease Diseases 0.000 description 2
• 108010010803 Gelatin Proteins 0.000 description 2
• 108010068370 Glutens Proteins 0.000 description 2
• 239000004471 Glycine Substances 0.000 description 2
• 201000005569 Gout Diseases 0.000 description 2
• WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
• 208000002250 Hematologic Neoplasms Diseases 0.000 description 2
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
• 102100022623 Hepatocyte growth factor receptor Human genes 0.000 description 2
• 102100035108 High affinity nerve growth factor receptor Human genes 0.000 description 2
• 241000282412 Homo Species 0.000 description 2
• 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 2
• 101000972946 Homo sapiens Hepatocyte growth factor receptor Proteins 0.000 description 2
• 206010020880 Hypertrophy Diseases 0.000 description 2
• 206010021143 Hypoxia Diseases 0.000 description 2
• XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
• 108060003951 Immunoglobulin Proteins 0.000 description 2
• 229930194542 Keto Natural products 0.000 description 2
• GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 2
• 108040008097 MAP kinase activity proteins Proteins 0.000 description 2
• 102000019149 MAP kinase activity proteins Human genes 0.000 description 2
• 239000007993 MOPS buffer Substances 0.000 description 2
• 208000001344 Macular Edema Diseases 0.000 description 2
• 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 2
• 206010027406 Mesothelioma Diseases 0.000 description 2
• 206010027480 Metastatic malignant melanoma Diseases 0.000 description 2
• 241001529936 Murinae Species 0.000 description 2
• 101100381978 Mus musculus Braf gene Proteins 0.000 description 2
• 208000037538 Myelomonocytic Juvenile Leukemia Diseases 0.000 description 2
• 206010028729 Nasal cavity cancer Diseases 0.000 description 2
• 206010028767 Nasal sinus cancer Diseases 0.000 description 2
• 101100247316 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) ras-1 gene Proteins 0.000 description 2
• 206010029748 Noonan syndrome Diseases 0.000 description 2
• 102100040479 P2X purinoceptor 2 Human genes 0.000 description 2
• 101710189968 P2X purinoceptor 2 Proteins 0.000 description 2
• 239000012661 PARP inhibitor Substances 0.000 description 2
• KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
• OQILCOQZDHPEAZ-UHFFFAOYSA-N Palmitinsaeure-octylester Natural products CCCCCCCCCCCCCCCC(=O)OCCCCCCCC OQILCOQZDHPEAZ-UHFFFAOYSA-N 0.000 description 2
• 208000031481 Pathologic Constriction Diseases 0.000 description 2
• 201000004014 Pfeiffer syndrome Diseases 0.000 description 2
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
• YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 2
• GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
• NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
• 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 description 2
• 229920001213 Polysorbate 20 Polymers 0.000 description 2
• 208000004550 Postoperative Pain Diseases 0.000 description 2
• 102000001788 Proto-Oncogene Proteins c-raf Human genes 0.000 description 2
• 108010029869 Proto-Oncogene Proteins c-raf Proteins 0.000 description 2
• 241000125945 Protoparvovirus Species 0.000 description 2
• 201000001263 Psoriatic Arthritis Diseases 0.000 description 2
• 208000036824 Psoriatic arthropathy Diseases 0.000 description 2
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
• 108091005682 Receptor kinases Proteins 0.000 description 2
• 206010038389 Renal cancer Diseases 0.000 description 2
• 206010061481 Renal injury Diseases 0.000 description 2
• 206010039085 Rhinitis allergic Diseases 0.000 description 2
• 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
• 229940124639 Selective inhibitor Drugs 0.000 description 2
• 244000166071 Shorea robusta Species 0.000 description 2
• 208000034254 Squamous cell carcinoma of the cervix uteri Diseases 0.000 description 2
• 208000035518 Squamous cell carcinoma of the oropharynx Diseases 0.000 description 2
• 229930006000 Sucrose Natural products 0.000 description 2
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
• 241000282898 Sus scrofa Species 0.000 description 2
• 208000007536 Thrombosis Diseases 0.000 description 2
• 239000007983 Tris buffer Substances 0.000 description 2
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
• 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 2
• 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 description 2
• 206010047115 Vasculitis Diseases 0.000 description 2
• 238000010521 absorption reaction Methods 0.000 description 2
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
• 230000002378 acidificating effect Effects 0.000 description 2
• 208000017733 acquired polycythemia vera Diseases 0.000 description 2
• 239000013543 active substance Substances 0.000 description 2
• 206010069351 acute lung injury Diseases 0.000 description 2
• 238000001042 affinity chromatography Methods 0.000 description 2
• 201000010105 allergic rhinitis Diseases 0.000 description 2
• 150000001413 amino acids Chemical group 0.000 description 2
• 125000003277 amino group Chemical group 0.000 description 2
• 239000004037 angiogenesis inhibitor Substances 0.000 description 2
• 229940121369 angiogenesis inhibitor Drugs 0.000 description 2
• 125000000129 anionic group Chemical group 0.000 description 2
• 150000001450 anions Chemical class 0.000 description 2
• 239000005557 antagonist Substances 0.000 description 2
• 230000001028 anti-proliverative effect Effects 0.000 description 2
• 238000010913 antigen-directed enzyme pro-drug therapy Methods 0.000 description 2
• 238000013459 approach Methods 0.000 description 2
• 229910052786 argon Inorganic materials 0.000 description 2
• 125000004429 atom Chemical group 0.000 description 2
• 230000009286 beneficial effect Effects 0.000 description 2
• PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 2
• 210000000481 breast Anatomy 0.000 description 2
• HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 2
• 230000036952 cancer formation Effects 0.000 description 2
• 210000000845 cartilage Anatomy 0.000 description 2
• 230000036755 cellular response Effects 0.000 description 2
• 230000005754 cellular signaling Effects 0.000 description 2
• 201000006612 cervical squamous cell carcinoma Diseases 0.000 description 2
• 230000008859 change Effects 0.000 description 2
• 208000037976 chronic inflammation Diseases 0.000 description 2
• 230000006020 chronic inflammation Effects 0.000 description 2
• 201000010902 chronic myelomonocytic leukemia Diseases 0.000 description 2
• 230000007882 cirrhosis Effects 0.000 description 2
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
• 229960004316 cisplatin Drugs 0.000 description 2
• 239000011248 coating agent Substances 0.000 description 2
• 238000000576 coating method Methods 0.000 description 2
• BSMCAPRUBJMWDF-KRWDZBQOSA-N cobimetinib Chemical compound C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F BSMCAPRUBJMWDF-KRWDZBQOSA-N 0.000 description 2
• 210000001072 colon Anatomy 0.000 description 2
• 239000000470 constituent Substances 0.000 description 2
• 238000011109 contamination Methods 0.000 description 2
• 239000013068 control sample Substances 0.000 description 2
• 238000001816 cooling Methods 0.000 description 2
• 239000002537 cosmetic Substances 0.000 description 2
• 230000006378 damage Effects 0.000 description 2
• 230000034994 death Effects 0.000 description 2
• 230000003247 decreasing effect Effects 0.000 description 2
• 238000000502 dialysis Methods 0.000 description 2
• 235000005911 diet Nutrition 0.000 description 2
• 230000037213 diet Effects 0.000 description 2
• 230000002900 effect on cell Effects 0.000 description 2
• 239000000839 emulsion Substances 0.000 description 2
• 239000007920 enema Substances 0.000 description 2
• 229940095399 enema Drugs 0.000 description 2
• 230000002708 enhancing effect Effects 0.000 description 2
• 208000037902 enteropathy Diseases 0.000 description 2
• 230000007613 environmental effect Effects 0.000 description 2
• BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 2
• 235000019439 ethyl acetate Nutrition 0.000 description 2
• 210000003414 extremity Anatomy 0.000 description 2
• 210000003754 fetus Anatomy 0.000 description 2
• 210000002950 fibroblast Anatomy 0.000 description 2
• 230000001842 fibrogenetic effect Effects 0.000 description 2
• 235000019634 flavors Nutrition 0.000 description 2
• 239000012530 fluid Substances 0.000 description 2
• VUWZPRWSIVNGKG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH2] VUWZPRWSIVNGKG-UHFFFAOYSA-N 0.000 description 2
• 239000006260 foam Substances 0.000 description 2
• 235000003599 food sweetener Nutrition 0.000 description 2
• 150000002270 gangliosides Chemical class 0.000 description 2
• 210000001035 gastrointestinal tract Anatomy 0.000 description 2
• 239000008273 gelatin Substances 0.000 description 2
• 229920000159 gelatin Polymers 0.000 description 2
• 235000019322 gelatine Nutrition 0.000 description 2
• 235000011852 gelatine desserts Nutrition 0.000 description 2
• 210000004907 gland Anatomy 0.000 description 2
• RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
• 235000021312 gluten Nutrition 0.000 description 2
• 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 2
• 210000002216 heart Anatomy 0.000 description 2
• 201000011066 hemangioma Diseases 0.000 description 2
• 229960002897 heparin Drugs 0.000 description 2
• 229920000669 heparin Polymers 0.000 description 2
• 230000002440 hepatic effect Effects 0.000 description 2
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
• 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 2
• 201000008298 histiocytosis Diseases 0.000 description 2
• 239000005556 hormone Substances 0.000 description 2
• BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 2
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
• 230000009610 hypersensitivity Effects 0.000 description 2
• 230000007954 hypoxia Effects 0.000 description 2
• 230000028993 immune response Effects 0.000 description 2
• 210000000987 immune system Anatomy 0.000 description 2
• 102000018358 immunoglobulin Human genes 0.000 description 2
• 238000003364 immunohistochemistry Methods 0.000 description 2
• 210000004969 inflammatory cell Anatomy 0.000 description 2
• 230000000977 initiatory effect Effects 0.000 description 2
• 208000014674 injury Diseases 0.000 description 2
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
• 208000028774 intestinal disease Diseases 0.000 description 2
• 230000009545 invasion Effects 0.000 description 2
• 238000011835 investigation Methods 0.000 description 2
• 208000002551 irritable bowel syndrome Diseases 0.000 description 2
• 239000012948 isocyanate Substances 0.000 description 2
• XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 2
• 229940043355 kinase inhibitor Drugs 0.000 description 2
• 210000000867 larynx Anatomy 0.000 description 2
• 239000010410 layer Substances 0.000 description 2
• 206010024217 lentigo Diseases 0.000 description 2
• GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 2
• 108010052968 leupeptin Proteins 0.000 description 2
• 230000000670 limiting effect Effects 0.000 description 2
• 206010024627 liposarcoma Diseases 0.000 description 2
• 239000002502 liposome Substances 0.000 description 2
• 239000000314 lubricant Substances 0.000 description 2
• 201000005243 lung squamous cell carcinoma Diseases 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 210000004962 mammalian cell Anatomy 0.000 description 2
• 238000005259 measurement Methods 0.000 description 2
• 239000012528 membrane Substances 0.000 description 2
• 230000004060 metabolic process Effects 0.000 description 2
• 208000021039 metastatic melanoma Diseases 0.000 description 2
• BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
• 230000011278 mitosis Effects 0.000 description 2
• 125000000896 monocarboxylic acid group Chemical group 0.000 description 2
• 150000004682 monohydrates Chemical class 0.000 description 2
• 230000000877 morphologic effect Effects 0.000 description 2
• 238000000465 moulding Methods 0.000 description 2
• 229940124303 multikinase inhibitor Drugs 0.000 description 2
• 208000031225 myocardial ischemia Diseases 0.000 description 2
• 210000003928 nasal cavity Anatomy 0.000 description 2
• 201000000494 nasal cavity squamous cell carcinoma Diseases 0.000 description 2
• 230000009826 neoplastic cell growth Effects 0.000 description 2
• 230000001537 neural effect Effects 0.000 description 2
• 229910052757 nitrogen Inorganic materials 0.000 description 2
• GQPLMRYTRLFLPF-UHFFFAOYSA-N nitrous oxide Inorganic materials [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 2
• 125000003729 nucleotide group Chemical group 0.000 description 2
• 238000011275 oncology therapy Methods 0.000 description 2
• 208000010655 oral cavity squamous cell carcinoma Diseases 0.000 description 2
• 150000002891 organic anions Chemical class 0.000 description 2
• 210000000963 osteoblast Anatomy 0.000 description 2
• 238000004806 packaging method and process Methods 0.000 description 2
• 239000012188 paraffin wax Substances 0.000 description 2
• 208000022697 paranasal sinus squamous cell carcinoma Diseases 0.000 description 2
• 230000036961 partial effect Effects 0.000 description 2
• 230000008506 pathogenesis Effects 0.000 description 2
• 230000001717 pathogenic effect Effects 0.000 description 2
• 230000007170 pathology Effects 0.000 description 2
• 230000007310 pathophysiology Effects 0.000 description 2
• 230000035515 penetration Effects 0.000 description 2
• YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
• 239000003757 phosphotransferase inhibitor Substances 0.000 description 2
• 238000002428 photodynamic therapy Methods 0.000 description 2
• 230000035790 physiological processes and functions Effects 0.000 description 2
• 239000006187 pill Substances 0.000 description 2
• 208000004748 plexiform neurofibroma Diseases 0.000 description 2
• 208000037244 polycythemia vera Diseases 0.000 description 2
• 229920005862 polyol Polymers 0.000 description 2
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
• 229920001184 polypeptide Polymers 0.000 description 2
• 229920000136 polysorbate Polymers 0.000 description 2
• 230000017363 positive regulation of growth Effects 0.000 description 2
• 230000002265 prevention Effects 0.000 description 2
• 230000000750 progressive effect Effects 0.000 description 2
• 125000006239 protecting group Chemical group 0.000 description 2
• LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 2
• 208000023504 respiratory system disease Diseases 0.000 description 2
• 230000003938 response to stress Effects 0.000 description 2
• 210000000574 retroperitoneal space Anatomy 0.000 description 2
• 210000003728 serous cell Anatomy 0.000 description 2
• 208000002491 severe combined immunodeficiency Diseases 0.000 description 2
• 230000035939 shock Effects 0.000 description 2
• 210000002460 smooth muscle Anatomy 0.000 description 2
• 210000000329 smooth muscle myocyte Anatomy 0.000 description 2
• 239000011734 sodium Substances 0.000 description 2
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
• 239000011780 sodium chloride Substances 0.000 description 2
• FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Inorganic materials [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
• 239000004334 sorbic acid Substances 0.000 description 2
• 235000010199 sorbic acid Nutrition 0.000 description 2
• 229940075582 sorbic acid Drugs 0.000 description 2
• 239000000600 sorbitol Substances 0.000 description 2
• 210000000278 spinal cord Anatomy 0.000 description 2
• 239000007921 spray Substances 0.000 description 2
• 210000000130 stem cell Anatomy 0.000 description 2
• 230000036262 stenosis Effects 0.000 description 2
• 208000037804 stenosis Diseases 0.000 description 2
• 210000002784 stomach Anatomy 0.000 description 2
• 238000007920 subcutaneous administration Methods 0.000 description 2
• 239000005720 sucrose Substances 0.000 description 2
• 239000006228 supernatant Substances 0.000 description 2
• 230000001629 suppression Effects 0.000 description 2
• 239000004094 surface-active agent Substances 0.000 description 2
• 239000003765 sweetening agent Substances 0.000 description 2
• 238000001308 synthesis method Methods 0.000 description 2
• 238000002626 targeted therapy Methods 0.000 description 2
• HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 2
• 238000004809 thin layer chromatography Methods 0.000 description 2
• 210000001685 thyroid gland Anatomy 0.000 description 2
• 230000009261 transgenic effect Effects 0.000 description 2
• 238000012250 transgenic expression Methods 0.000 description 2
• 238000002054 transplantation Methods 0.000 description 2
• CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 2
• 229940029284 trichlorofluoromethane Drugs 0.000 description 2
• 229940086542 triethylamine Drugs 0.000 description 2
• 230000004614 tumor growth Effects 0.000 description 2
• 241000712461 unidentified influenza virus Species 0.000 description 2
• 201000005112 urinary bladder cancer Diseases 0.000 description 2
• 208000024719 uterine cervix neoplasm Diseases 0.000 description 2
• 210000005166 vasculature Anatomy 0.000 description 2
• LLDWLPRYLVPDTG-UHFFFAOYSA-N vatalanib succinate Chemical compound OC(=O)CCC(O)=O.C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 LLDWLPRYLVPDTG-UHFFFAOYSA-N 0.000 description 2
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
• 229940034727 zelboraf Drugs 0.000 description 2
• 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
• QMMJWQMCMRUYTG-UHFFFAOYSA-N 1,2,4,5-tetrachloro-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=C(Cl)C(Cl)=CC(Cl)=C1Cl QMMJWQMCMRUYTG-UHFFFAOYSA-N 0.000 description 1
• OMOCVUPRTIPABZ-UHFFFAOYSA-N 1-(1h-imidazol-2-yl)piperidine Chemical compound C1CCCCN1C1=NC=CN1 OMOCVUPRTIPABZ-UHFFFAOYSA-N 0.000 description 1
• TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
• 102000001556 1-Phosphatidylinositol 4-Kinase Human genes 0.000 description 1
• 108010029190 1-Phosphatidylinositol 4-Kinase Proteins 0.000 description 1
• LGEZTMRIZWCDLW-UHFFFAOYSA-N 14-methylpentadecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC(C)C LGEZTMRIZWCDLW-UHFFFAOYSA-N 0.000 description 1
• 238000004293 19F NMR spectroscopy Methods 0.000 description 1
• JVVRJMXHNUAPHW-UHFFFAOYSA-N 1h-pyrazol-5-amine Chemical group NC=1C=CNN=1 JVVRJMXHNUAPHW-UHFFFAOYSA-N 0.000 description 1
• XAEGRAIWWBXIRR-UHFFFAOYSA-N 1h-pyrazol-5-ylurea Chemical class NC(=O)NC=1C=CNN=1 XAEGRAIWWBXIRR-UHFFFAOYSA-N 0.000 description 1
• KOPFEFZSAMLEHK-UHFFFAOYSA-M 1h-pyrazole-5-carboxylate Chemical compound [O-]C(=O)C=1C=CNN=1 KOPFEFZSAMLEHK-UHFFFAOYSA-M 0.000 description 1
• DCBOUXKSNFDXER-UHFFFAOYSA-N 1h-pyrido[2,3-b]pyrazin-2-one Chemical class C1=CC=C2NC(=O)C=NC2=N1 DCBOUXKSNFDXER-UHFFFAOYSA-N 0.000 description 1
• NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
• HKEWOTUTAYJWQJ-UHFFFAOYSA-N 2-(1h-pyrazol-5-yl)pyridine Chemical compound N1N=CC=C1C1=CC=CC=N1 HKEWOTUTAYJWQJ-UHFFFAOYSA-N 0.000 description 1
• GXVUZYLYWKWJIM-UHFFFAOYSA-N 2-(2-aminoethoxy)ethanamine Chemical compound NCCOCCN GXVUZYLYWKWJIM-UHFFFAOYSA-N 0.000 description 1
• GFMMXOIFOQCCGU-UHFFFAOYSA-N 2-(2-chloro-4-iodoanilino)-N-(cyclopropylmethoxy)-3,4-difluorobenzamide Chemical compound C=1C=C(I)C=C(Cl)C=1NC1=C(F)C(F)=CC=C1C(=O)NOCC1CC1 GFMMXOIFOQCCGU-UHFFFAOYSA-N 0.000 description 1
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
• CDAWCLOXVUBKRW-UHFFFAOYSA-N 2-aminophenol Chemical class NC1=CC=CC=C1O CDAWCLOXVUBKRW-UHFFFAOYSA-N 0.000 description 1
• 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 1
• WVCHIGAIXREVNS-UHFFFAOYSA-N 2-hydroxy-1,4-naphthoquinone Chemical compound C1=CC=C2C(O)=CC(=O)C(=O)C2=C1 WVCHIGAIXREVNS-UHFFFAOYSA-N 0.000 description 1
• UPHOPMSGKZNELG-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1 UPHOPMSGKZNELG-UHFFFAOYSA-N 0.000 description 1
• IWTFOFMTUOBLHG-UHFFFAOYSA-N 2-methoxypyridine Chemical compound COC1=CC=CC=N1 IWTFOFMTUOBLHG-UHFFFAOYSA-N 0.000 description 1
• MSYGAHOHLUJIKV-UHFFFAOYSA-N 3,5-dimethyl-1-(3-nitrophenyl)-1h-pyrazole-4-carboxylic acid ethyl ester Chemical compound CC1=C(C(=O)OCC)C(C)=NN1C1=CC=CC([N+]([O-])=O)=C1 MSYGAHOHLUJIKV-UHFFFAOYSA-N 0.000 description 1
• FOSJLAHTWYZRGP-UHFFFAOYSA-N 3-(4-aminophenoxy)-1H-pyrido[2,3-b]pyrazin-2-one Chemical compound NC1=CC=C(OC=2C(NC3=C(N2)N=CC=C3)=O)C=C1 FOSJLAHTWYZRGP-UHFFFAOYSA-N 0.000 description 1
• WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 1
• 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
• MXZMACXOMZKYHJ-UHFFFAOYSA-N 4,4-dimethyl-3-oxopentanenitrile Chemical compound CC(C)(C)C(=O)CC#N MXZMACXOMZKYHJ-UHFFFAOYSA-N 0.000 description 1
• OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
• 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
• QOVGZKZWSXKFGS-UHFFFAOYSA-N 5-tert-butyl-2-(3-methoxyphenyl)pyrazole-3-carboxylic acid Chemical compound C(C)(C)(C)C1=NN(C(=C1)C(=O)O)C1=CC(=CC=C1)OC QOVGZKZWSXKFGS-UHFFFAOYSA-N 0.000 description 1
• OWWZNLRWZRVATO-UHFFFAOYSA-N 5-tert-butyl-2-(4-methoxyphenyl)pyrazole-3-carboxylic acid Chemical compound COc1ccc(cc1)-n1nc(cc1C(O)=O)C(C)(C)C OWWZNLRWZRVATO-UHFFFAOYSA-N 0.000 description 1
• BTGMFQHKNSUENT-UHFFFAOYSA-N 5-tert-butyl-2-[3-(trifluoromethyl)phenyl]pyrazole-3-carboxylic acid Chemical compound C(C)(C)(C)C1=NN(C(=C1)C(=O)O)C1=CC(=CC=C1)C(F)(F)F BTGMFQHKNSUENT-UHFFFAOYSA-N 0.000 description 1
• XEIVCDDCSGGZSG-UHFFFAOYSA-N 7-[3-[(3-formylphenoxy)methyl]-1,5-dimethylpyrazol-4-yl]-3-(3-naphthalen-1-yloxypropyl)-1H-indole-2-carboxylic acid Chemical compound Cc1c(c(COc2cccc(C=O)c2)nn1C)-c1cccc2c(CCCOc3cccc4ccccc34)c([nH]c12)C(O)=O XEIVCDDCSGGZSG-UHFFFAOYSA-N 0.000 description 1
• BDDLHHRCDSJVKV-UHFFFAOYSA-N 7028-40-2 Chemical compound CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O BDDLHHRCDSJVKV-UHFFFAOYSA-N 0.000 description 1
• RJOQGLYSNVGSHJ-UHFFFAOYSA-N 8-(4-amino-3-fluorophenoxy)-4h-pyrido[2,3-b]pyrazin-3-one Chemical compound C1=C(F)C(N)=CC=C1OC1=CC=NC2=C1N=CC(=O)N2 RJOQGLYSNVGSHJ-UHFFFAOYSA-N 0.000 description 1
• 101150108281 ADL1 gene Proteins 0.000 description 1
• 208000030507 AIDS Diseases 0.000 description 1
• 108091008717 AR-A Proteins 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• 208000004476 Acute Coronary Syndrome Diseases 0.000 description 1
• 206010001150 Adenocarcinoma gastric Diseases 0.000 description 1
• 206010001497 Agitation Diseases 0.000 description 1
• 208000007848 Alcoholism Diseases 0.000 description 1
• 229930183010 Amphotericin Natural products 0.000 description 1
• QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 description 1
• 206010002091 Anaesthesia Diseases 0.000 description 1
• 208000001446 Anaplastic Thyroid Carcinoma Diseases 0.000 description 1
• 206010002240 Anaplastic thyroid cancer Diseases 0.000 description 1
• 102000009088 Angiopoietin-1 Human genes 0.000 description 1
• 108010048154 Angiopoietin-1 Proteins 0.000 description 1
• 102400000068 Angiostatin Human genes 0.000 description 1
• 108010079709 Angiostatins Proteins 0.000 description 1
• 201000002862 Angle-Closure Glaucoma Diseases 0.000 description 1
• 108010083359 Antigen Receptors Proteins 0.000 description 1
• 102000006306 Antigen Receptors Human genes 0.000 description 1
• 108010039627 Aprotinin Proteins 0.000 description 1
• 108091023037 Aptamer Proteins 0.000 description 1
• 101100332244 Arabidopsis thaliana DRP1A gene Proteins 0.000 description 1
• 239000004475 Arginine Substances 0.000 description 1
• 241001132374 Asta Species 0.000 description 1
• 206010003658 Atrial Fibrillation Diseases 0.000 description 1
• 208000023275 Autoimmune disease Diseases 0.000 description 1
• 241000271566 Aves Species 0.000 description 1
• 208000000412 Avitaminosis Diseases 0.000 description 1
• IVRMZWNICZWHMI-UHFFFAOYSA-N Azide Chemical compound [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 1
• 208000037157 Azotemia Diseases 0.000 description 1
• MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
• 208000035143 Bacterial infection Diseases 0.000 description 1
• 208000008720 Bone Marrow Neoplasms Diseases 0.000 description 1
• 241000283725 Bos Species 0.000 description 1
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
• 208000003174 Brain Neoplasms Diseases 0.000 description 1
• COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
• 239000004358 Butane-1, 3-diol Substances 0.000 description 1
• 102000000905 Cadherin Human genes 0.000 description 1
• 108050007957 Cadherin Proteins 0.000 description 1
• 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• 206010058019 Cancer Pain Diseases 0.000 description 1
• 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
• 208000020446 Cardiac disease Diseases 0.000 description 1
• 206010007558 Cardiac failure chronic Diseases 0.000 description 1
• 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
• 201000002927 Cardiofaciocutaneous syndrome Diseases 0.000 description 1
• 208000006029 Cardiomegaly Diseases 0.000 description 1
• 208000024172 Cardiovascular disease Diseases 0.000 description 1
• 102000014914 Carrier Proteins Human genes 0.000 description 1
• 102000016362 Catenins Human genes 0.000 description 1
• 108010067316 Catenins Proteins 0.000 description 1
• 241000700199 Cavia porcellus Species 0.000 description 1
• 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
• 201000006082 Chickenpox Diseases 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
• 208000005243 Chondrosarcoma Diseases 0.000 description 1
• 108010077544 Chromatin Proteins 0.000 description 1
• 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
• 241000725101 Clea Species 0.000 description 1
• 235000013162 Cocos nucifera Nutrition 0.000 description 1
• 244000060011 Cocos nucifera Species 0.000 description 1
• 201000003874 Common Variable Immunodeficiency Diseases 0.000 description 1
• 208000009283 Craniosynostoses Diseases 0.000 description 1
• 206010049889 Craniosynostosis Diseases 0.000 description 1
• 241000699800 Cricetinae Species 0.000 description 1
• 241000699802 Cricetulus griseus Species 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• 230000004544 DNA amplification Effects 0.000 description 1
• 238000011238 DNA vaccination Methods 0.000 description 1
• 241000252212 Danio rerio Species 0.000 description 1
• 241000238557 Decapoda Species 0.000 description 1
• 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
• 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
• 101000876610 Dictyostelium discoideum Extracellular signal-regulated kinase 2 Proteins 0.000 description 1
• XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
• BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
• 101100291385 Drosophila melanogaster p38a gene Proteins 0.000 description 1
• 102100023266 Dual specificity mitogen-activated protein kinase kinase 2 Human genes 0.000 description 1
• 102100023272 Dual specificity mitogen-activated protein kinase kinase 5 Human genes 0.000 description 1
• 101710146524 Dual specificity mitogen-activated protein kinase kinase 5 Proteins 0.000 description 1
• 102100036492 Dual specificity testis-specific protein kinase 1 Human genes 0.000 description 1
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
• 208000005189 Embolism Diseases 0.000 description 1
• 206010014664 Endocardial fibrosis Diseases 0.000 description 1
• 208000037487 Endotoxemia Diseases 0.000 description 1
• 102000050554 Eph Family Receptors Human genes 0.000 description 1
• 108091008815 Eph receptors Proteins 0.000 description 1
• 101800003838 Epidermal growth factor Proteins 0.000 description 1
• 206010015150 Erythema Diseases 0.000 description 1
• 241000588724 Escherichia coli Species 0.000 description 1
• VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
• 239000005977 Ethylene Substances 0.000 description 1
• PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
• 229910052693 Europium Inorganic materials 0.000 description 1
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
• 102000036353 FBXWs Human genes 0.000 description 1
• 108091007023 FBXWs Proteins 0.000 description 1
• CJGJKNZZCZXWCE-UHFFFAOYSA-N FC1=C(C=CC(=C1)OC1=CC=NC=2NC(C=NC=21)=O)NC(N)=O Chemical compound FC1=C(C=CC(=C1)OC1=CC=NC=2NC(C=NC=21)=O)NC(N)=O CJGJKNZZCZXWCE-UHFFFAOYSA-N 0.000 description 1
• 239000001263 FEMA 3042 Substances 0.000 description 1
• 208000013452 Fallopian tube neoplasm Diseases 0.000 description 1
• 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 1
• 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 1
• 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
• 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
• 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
• 102100027844 Fibroblast growth factor receptor 4 Human genes 0.000 description 1
• 206010053717 Fibrous histiocytoma Diseases 0.000 description 1
• 102000039539 Fos family Human genes 0.000 description 1
• 108091067362 Fos family Proteins 0.000 description 1
• 108091006027 G proteins Proteins 0.000 description 1
• 102000034286 G proteins Human genes 0.000 description 1
• 102000018898 GTPase-Activating Proteins Human genes 0.000 description 1
• 108091006094 GTPase-accelerating proteins Proteins 0.000 description 1
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
• 108010024636 Glutathione Proteins 0.000 description 1
• 206010018634 Gouty Arthritis Diseases 0.000 description 1
• HSRJKNPTNIJEKV-UHFFFAOYSA-N Guaifenesin Chemical compound COC1=CC=CC=C1OCC(O)CO HSRJKNPTNIJEKV-UHFFFAOYSA-N 0.000 description 1
• 102100025334 Guanine nucleotide-binding protein G(q) subunit alpha Human genes 0.000 description 1
• 239000007995 HEPES buffer Substances 0.000 description 1
• 108010068308 Hemoglobin H Proteins 0.000 description 1
• 241000711549 Hepacivirus C Species 0.000 description 1
• 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 1
• 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 1
• 206010019842 Hepatomegaly Diseases 0.000 description 1
• 241000238631 Hexapoda Species 0.000 description 1
• 206010020118 Histiocytoses Diseases 0.000 description 1
• 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 1
• 101001014196 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 1 Proteins 0.000 description 1
• 101000714159 Homo sapiens Dual specificity testis-specific protein kinase 1 Proteins 0.000 description 1
• 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 description 1
• 101000917134 Homo sapiens Fibroblast growth factor receptor 4 Proteins 0.000 description 1
• 101000857888 Homo sapiens Guanine nucleotide-binding protein G(q) subunit alpha Proteins 0.000 description 1
• 101000573441 Homo sapiens Misshapen-like kinase 1 Proteins 0.000 description 1
• 101001052493 Homo sapiens Mitogen-activated protein kinase 1 Proteins 0.000 description 1
• 101000958041 Homo sapiens Musculin Proteins 0.000 description 1
• 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 1
• 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
• 101001091984 Homo sapiens Rho GTPase-activating protein 26 Proteins 0.000 description 1
• 101000713585 Homo sapiens Tubulin beta-4A chain Proteins 0.000 description 1
• 101000753253 Homo sapiens Tyrosine-protein kinase receptor Tie-1 Proteins 0.000 description 1
• 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 1
• 241000193096 Human adenovirus B3 Species 0.000 description 1
• 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
• 241000701589 Human papillomavirus type 6b Species 0.000 description 1
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
• 241000282596 Hylobatidae Species 0.000 description 1
• 208000004454 Hyperalgesia Diseases 0.000 description 1
• 206010021135 Hypovitaminosis Diseases 0.000 description 1
• 208000024934 IgG4-related mediastinitis Diseases 0.000 description 1
• 108010001160 IgY Proteins 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 208000029462 Immunodeficiency disease Diseases 0.000 description 1
• 238000012404 In vitro experiment Methods 0.000 description 1
• 102100023915 Insulin Human genes 0.000 description 1
• 108090001061 Insulin Proteins 0.000 description 1
• 108090001007 Interleukin-8 Proteins 0.000 description 1
• 102100026236 Interleukin-8 Human genes 0.000 description 1
• 206010061252 Intraocular melanoma Diseases 0.000 description 1
• 241000976416 Isatis tinctoria subsp. canescens Species 0.000 description 1
• PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
• 208000009289 Jackson-Weiss syndrome Diseases 0.000 description 1
• 206010069755 K-ras gene mutation Diseases 0.000 description 1
• 208000008839 Kidney Neoplasms Diseases 0.000 description 1
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
• 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
• 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
• JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 235000019687 Lamb Nutrition 0.000 description 1
• 201000005099 Langerhans cell histiocytosis Diseases 0.000 description 1
• 241000272168 Laridae Species 0.000 description 1
• 206010023856 Laryngeal squamous cell carcinoma Diseases 0.000 description 1
• 208000006552 Lewis Lung Carcinoma Diseases 0.000 description 1
• 241000234435 Lilium Species 0.000 description 1
• 241001233242 Lontra Species 0.000 description 1
• 241000336847 Luda Species 0.000 description 1
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
• 241000195954 Lycopodium clavatum Species 0.000 description 1
• 239000004472 Lysine Substances 0.000 description 1
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
• 108010068342 MAP Kinase Kinase 1 Proteins 0.000 description 1
• 108010068353 MAP Kinase Kinase 2 Proteins 0.000 description 1
• 241000289581 Macropus sp. Species 0.000 description 1
• 206010025421 Macule Diseases 0.000 description 1
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
• 206010025654 Malignant melanoma of sites other than skin Diseases 0.000 description 1
• 206010061269 Malignant peritoneal neoplasm Diseases 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
• 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
• 208000002805 Mediastinal fibrosis Diseases 0.000 description 1
• 108010052285 Membrane Proteins Proteins 0.000 description 1
• 208000001145 Metabolic Syndrome Diseases 0.000 description 1
• 206010059282 Metastases to central nervous system Diseases 0.000 description 1
• 206010063569 Metastatic squamous cell carcinoma Diseases 0.000 description 1
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
• 208000019695 Migraine disease Diseases 0.000 description 1
• 102100026287 Misshapen-like kinase 1 Human genes 0.000 description 1
• 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 1
• 102100026888 Mitogen-activated protein kinase kinase kinase 7 Human genes 0.000 description 1
• 241000699660 Mus musculus Species 0.000 description 1
• 208000029549 Muscle injury Diseases 0.000 description 1
• 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
• 206010028594 Myocardial fibrosis Diseases 0.000 description 1
• WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
• OQRNUIHAKUIWIF-UHFFFAOYSA-N N-benzylaniline Chemical compound C(C1=CC=CC=C1)NC1=CC=CC=C1.C1(=CC=CC=C1)NCC1=CC=CC=C1 OQRNUIHAKUIWIF-UHFFFAOYSA-N 0.000 description 1
• 108050000637 N-cadherin Proteins 0.000 description 1
• MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
• 108010057466 NF-kappa B Proteins 0.000 description 1
• 102000003945 NF-kappa B Human genes 0.000 description 1
• 101150111783 NTRK1 gene Proteins 0.000 description 1
• 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
• 206010061309 Neoplasm progression Diseases 0.000 description 1
• 208000005289 Neoplastic Cell Transformation Diseases 0.000 description 1
• 206010029113 Neovascularisation Diseases 0.000 description 1
• 208000028389 Nerve injury Diseases 0.000 description 1
• 208000012902 Nervous system disease Diseases 0.000 description 1
• 208000009277 Neuroectodermal Tumors Diseases 0.000 description 1
• 208000003019 Neurofibromatosis 1 Diseases 0.000 description 1
• 208000024834 Neurofibromatosis type 1 Diseases 0.000 description 1
• 208000036110 Neuroinflammatory disease Diseases 0.000 description 1
• 206010029488 Nodular melanoma Diseases 0.000 description 1
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
• 208000011623 Obstructive Lung disease Diseases 0.000 description 1
• 208000022873 Ocular disease Diseases 0.000 description 1
• 206010030113 Oedema Diseases 0.000 description 1
• 206010030216 Oesophagitis Diseases 0.000 description 1
• 102000043276 Oncogene Human genes 0.000 description 1
• 206010030348 Open-Angle Glaucoma Diseases 0.000 description 1
• 108091008606 PDGF receptors Proteins 0.000 description 1
• 241000282579 Pan Species 0.000 description 1
• 241000845082 Panama Species 0.000 description 1
• 235000016496 Panda oleosa Nutrition 0.000 description 1
• 240000000220 Panda oleosa Species 0.000 description 1
• 241000282520 Papio Species 0.000 description 1
• 208000030852 Parasitic disease Diseases 0.000 description 1
• 208000018737 Parkinson disease Diseases 0.000 description 1
• 208000034038 Pathologic Neovascularization Diseases 0.000 description 1
• 102000018546 Paxillin Human genes 0.000 description 1
• ACNHBCIZLNNLRS-UHFFFAOYSA-N Paxilline 1 Natural products N1C2=CC=CC=C2C2=C1C1(C)C3(C)CCC4OC(C(C)(O)C)C(=O)C=C4C3(O)CCC1C2 ACNHBCIZLNNLRS-UHFFFAOYSA-N 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 206010061336 Pelvic neoplasm Diseases 0.000 description 1
• LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
• 206010034464 Periarthritis Diseases 0.000 description 1
• 208000037581 Persistent Infection Diseases 0.000 description 1
• 208000004983 Phantom Limb Diseases 0.000 description 1
• 206010056238 Phantom pain Diseases 0.000 description 1
• 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 description 1
• 241000709664 Picornaviridae Species 0.000 description 1
• 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 1
• 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• 241000282405 Pongo abelii Species 0.000 description 1
• 206010036376 Postherpetic Neuralgia Diseases 0.000 description 1
• 208000026149 Primary peritoneal carcinoma Diseases 0.000 description 1
• 241000288906 Primates Species 0.000 description 1
• 102100024622 Proenkephalin-B Human genes 0.000 description 1
• 108090000315 Protein Kinase C Proteins 0.000 description 1
• 102000003923 Protein Kinase C Human genes 0.000 description 1
• 102000052575 Proto-Oncogene Human genes 0.000 description 1
• 108700020978 Proto-Oncogene Proteins 0.000 description 1
• 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
• 102000042888 RAF family Human genes 0.000 description 1
• 108091082327 RAF family Proteins 0.000 description 1
• 102000015097 RNA Splicing Factors Human genes 0.000 description 1
• 108010039259 RNA Splicing Factors Proteins 0.000 description 1
• 206010037779 Radiculopathy Diseases 0.000 description 1
• 229940078123 Ras inhibitor Drugs 0.000 description 1
• 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 description 1
• 101000852966 Rattus norvegicus Interleukin-1 receptor-like 1 Proteins 0.000 description 1
• 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
• 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
• 208000033464 Reiter syndrome Diseases 0.000 description 1
• 208000006265 Renal cell carcinoma Diseases 0.000 description 1
• 206010063837 Reperfusion injury Diseases 0.000 description 1
• 206010038687 Respiratory distress Diseases 0.000 description 1
• 208000017442 Retinal disease Diseases 0.000 description 1
• 206010038923 Retinopathy Diseases 0.000 description 1
• 206010038933 Retinopathy of prematurity Diseases 0.000 description 1
• 102100035744 Rho GTPase-activating protein 26 Human genes 0.000 description 1
• 241000283984 Rodentia Species 0.000 description 1
• RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
• 206010039710 Scleroderma Diseases 0.000 description 1
• 201000010208 Seminoma Diseases 0.000 description 1
• 206010040047 Sepsis Diseases 0.000 description 1
• 206010040914 Skin reaction Diseases 0.000 description 1
• NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
• 208000005392 Spasm Diseases 0.000 description 1
• 206010041591 Spinal osteoarthritis Diseases 0.000 description 1
• 206010041849 Squamous cell carcinoma of the hypopharynx Diseases 0.000 description 1
• 208000036844 Squamous cell carcinoma of the larynx Diseases 0.000 description 1
• 208000034299 Squamous cell carcinoma of the lip Diseases 0.000 description 1
• 206010041857 Squamous cell carcinoma of the oral cavity Diseases 0.000 description 1
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
• 201000009594 Systemic Scleroderma Diseases 0.000 description 1
• 206010042953 Systemic sclerosis Diseases 0.000 description 1
• 230000006044 T cell activation Effects 0.000 description 1
• 230000006052 T cell proliferation Effects 0.000 description 1
• 210000001744 T-lymphocyte Anatomy 0.000 description 1
• 102000005450 TIE receptors Human genes 0.000 description 1
• 108010006830 TIE receptors Proteins 0.000 description 1
• 108010090091 TIE-2 Receptor Proteins 0.000 description 1
• 102000012753 TIE-2 Receptor Human genes 0.000 description 1
• 108700012920 TNF Proteins 0.000 description 1
• 108700031954 Tgfb1i1/Leupaxin/TGFB1I1 Proteins 0.000 description 1
• 208000002903 Thalassemia Diseases 0.000 description 1
• 208000033781 Thyroid carcinoma Diseases 0.000 description 1
• 208000024799 Thyroid disease Diseases 0.000 description 1
• 206010062129 Tongue neoplasm Diseases 0.000 description 1
• 229920001615 Tragacanth Polymers 0.000 description 1
• 108090000340 Transaminases Proteins 0.000 description 1
• 241000224526 Trichomonas Species 0.000 description 1
• 229920004890 Triton X-100 Polymers 0.000 description 1
• 102000004142 Trypsin Human genes 0.000 description 1
• 108090000631 Trypsin Proteins 0.000 description 1
• 102100036788 Tubulin beta-4A chain Human genes 0.000 description 1
• 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
• 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
• 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 description 1
• 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 description 1
• 102100022007 Tyrosine-protein kinase receptor Tie-1 Human genes 0.000 description 1
• 102220531375 Uncharacterized protein KIAA2012_Q16K_mutation Human genes 0.000 description 1
• 206010046980 Varicella Diseases 0.000 description 1
• 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 1
• 102000016663 Vascular Endothelial Growth Factor Receptor-3 Human genes 0.000 description 1
• 206010047139 Vasoconstriction Diseases 0.000 description 1
• 235000009754 Vitis X bourquina Nutrition 0.000 description 1
• 235000012333 Vitis X labruscana Nutrition 0.000 description 1
• 240000006365 Vitis vinifera Species 0.000 description 1
• 235000014787 Vitis vinifera Nutrition 0.000 description 1
• SORGEQQSQGNZFI-UHFFFAOYSA-N [azido(phenoxy)phosphoryl]oxybenzene Chemical compound C=1C=CC=CC=1OP(=O)(N=[N+]=[N-])OC1=CC=CC=C1 SORGEQQSQGNZFI-UHFFFAOYSA-N 0.000 description 1
• 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
• 230000001594 aberrant effect Effects 0.000 description 1
• JIUIIWVYHWSFAZ-UHFFFAOYSA-N ac1o0v2m Chemical compound O.O.O.O.O JIUIIWVYHWSFAZ-UHFFFAOYSA-N 0.000 description 1
• VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 239000004480 active ingredient Substances 0.000 description 1
• 230000009692 acute damage Effects 0.000 description 1
• 208000024340 acute graft versus host disease Diseases 0.000 description 1
• 208000038016 acute inflammation Diseases 0.000 description 1
• 230000006022 acute inflammation Effects 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 230000000996 additive effect Effects 0.000 description 1
• 208000020990 adrenal cortex carcinoma Diseases 0.000 description 1
• 230000002411 adverse Effects 0.000 description 1
• 150000001298 alcohols Chemical class 0.000 description 1
• 125000003172 aldehyde group Chemical group 0.000 description 1
• 150000001299 aldehydes Chemical class 0.000 description 1
• 229910001413 alkali metal ion Inorganic materials 0.000 description 1
• 125000005907 alkyl ester group Chemical group 0.000 description 1
• 230000029936 alkylation Effects 0.000 description 1
• 238000005804 alkylation reaction Methods 0.000 description 1
• 201000009961 allergic asthma Diseases 0.000 description 1
• 208000002029 allergic contact dermatitis Diseases 0.000 description 1
• 230000007815 allergy Effects 0.000 description 1
• AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
• 230000001668 ameliorated effect Effects 0.000 description 1
• 150000001408 amides Chemical class 0.000 description 1
• 150000001409 amidines Chemical class 0.000 description 1
• VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
• 229940009444 amphotericin Drugs 0.000 description 1
• APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
• 238000002266 amputation Methods 0.000 description 1
• 230000037005 anaesthesia Effects 0.000 description 1
• 230000003698 anagen phase Effects 0.000 description 1
• 239000003098 androgen Substances 0.000 description 1
• 208000007502 anemia Diseases 0.000 description 1
• 239000002870 angiogenesis inducing agent Substances 0.000 description 1
• 230000002491 angiogenic effect Effects 0.000 description 1
• 230000006481 angiogenic pathway Effects 0.000 description 1
• 230000006427 angiogenic response Effects 0.000 description 1
• 238000002399 angioplasty Methods 0.000 description 1
• 230000001772 anti-angiogenic effect Effects 0.000 description 1
• 230000002456 anti-arthritic effect Effects 0.000 description 1
• 230000001093 anti-cancer Effects 0.000 description 1
• 230000000340 anti-metabolite Effects 0.000 description 1
• 230000002555 anti-neurodegenerative effect Effects 0.000 description 1
• 229940100197 antimetabolite Drugs 0.000 description 1
• 239000002256 antimetabolite Substances 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 239000003443 antiviral agent Substances 0.000 description 1
• 238000003782 apoptosis assay Methods 0.000 description 1
• IMOZEMNVLZVGJZ-QGZVFWFLSA-N apremilast Chemical compound C1=C(OC)C(OCC)=CC([C@@H](CS(C)(=O)=O)N2C(C3=C(NC(C)=O)C=CC=C3C2=O)=O)=C1 IMOZEMNVLZVGJZ-QGZVFWFLSA-N 0.000 description 1
• 229960001164 apremilast Drugs 0.000 description 1
• 229960004405 aprotinin Drugs 0.000 description 1
• 239000008346 aqueous phase Substances 0.000 description 1
• 239000003125 aqueous solvent Substances 0.000 description 1
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
• 150000004982 aromatic amines Chemical class 0.000 description 1
• 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
• 238000006254 arylation reaction Methods 0.000 description 1
• FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
• 230000001363 autoimmune Effects 0.000 description 1
• 230000006472 autoimmune response Effects 0.000 description 1
• 230000035578 autophosphorylation Effects 0.000 description 1
• 230000003376 axonal effect Effects 0.000 description 1
• FDNFFHUEVRMJSE-UHFFFAOYSA-N azane butane Chemical compound N.N.CCCC FDNFFHUEVRMJSE-UHFFFAOYSA-N 0.000 description 1
• 208000022362 bacterial infectious disease Diseases 0.000 description 1
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
• AFYNADDZULBEJA-UHFFFAOYSA-N bicinchoninic acid Chemical compound C1=CC=CC2=NC(C=3C=C(C4=CC=CC=C4N=3)C(=O)O)=CC(C(O)=O)=C21 AFYNADDZULBEJA-UHFFFAOYSA-N 0.000 description 1
• 210000000941 bile Anatomy 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 108091008324 binding proteins Proteins 0.000 description 1
• 230000004071 biological effect Effects 0.000 description 1
• 230000005540 biological transmission Effects 0.000 description 1
• 206010005084 bladder transitional cell carcinoma Diseases 0.000 description 1
• 201000001528 bladder urothelial carcinoma Diseases 0.000 description 1
• 201000000053 blastoma Diseases 0.000 description 1
• 239000002981 blocking agent Substances 0.000 description 1
• 210000001124 body fluid Anatomy 0.000 description 1
• 230000037396 body weight Effects 0.000 description 1
• 210000001185 bone marrow Anatomy 0.000 description 1
• 201000006491 bone marrow cancer Diseases 0.000 description 1
• 208000019664 bone resorption disease Diseases 0.000 description 1
• ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
• 208000029028 brain injury Diseases 0.000 description 1
• 239000001273 butane Substances 0.000 description 1
• 235000019437 butane-1,3-diol Nutrition 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
• 208000035269 cancer or benign tumor Diseases 0.000 description 1
• 239000012830 cancer therapeutic Substances 0.000 description 1
• 239000007894 caplet Substances 0.000 description 1
• 239000001569 carbon dioxide Substances 0.000 description 1
• 229910002092 carbon dioxide Inorganic materials 0.000 description 1
• SKOLWUPSYHWYAM-UHFFFAOYSA-N carbonodithioic O,S-acid Chemical compound SC(S)=O SKOLWUPSYHWYAM-UHFFFAOYSA-N 0.000 description 1
• 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
• 125000002843 carboxylic acid group Chemical group 0.000 description 1
• 150000001735 carboxylic acids Chemical class 0.000 description 1
• 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
• 208000022033 carcinoma of urethra Diseases 0.000 description 1
• 230000000747 cardiac effect Effects 0.000 description 1
• 238000012754 cardiac puncture Methods 0.000 description 1
• 230000015556 catabolic process Effects 0.000 description 1
• 230000003197 catalytic effect Effects 0.000 description 1
• 238000004113 cell culture Methods 0.000 description 1
• 230000030833 cell death Effects 0.000 description 1
• 230000012292 cell migration Effects 0.000 description 1
• 230000009087 cell motility Effects 0.000 description 1
• 230000003833 cell viability Effects 0.000 description 1
• 210000002421 cell wall Anatomy 0.000 description 1
• 230000017455 cell-cell adhesion Effects 0.000 description 1
• 210000003169 central nervous system Anatomy 0.000 description 1
• 235000013339 cereals Nutrition 0.000 description 1
• 208000029771 childhood onset asthma Diseases 0.000 description 1
• OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
• 229960001231 choline Drugs 0.000 description 1
• 210000003483 chromatin Anatomy 0.000 description 1
• 238000004587 chromatography analysis Methods 0.000 description 1
• 230000002759 chromosomal effect Effects 0.000 description 1
• 230000009693 chronic damage Effects 0.000 description 1
• 208000017760 chronic graft versus host disease Diseases 0.000 description 1
• LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
• 239000003245 coal Substances 0.000 description 1
• 229940110456 cocoa butter Drugs 0.000 description 1
• 235000019868 cocoa butter Nutrition 0.000 description 1
• 239000003086 colorant Substances 0.000 description 1
• 238000007398 colorimetric assay Methods 0.000 description 1
• 238000002648 combination therapy Methods 0.000 description 1
• 238000011284 combination treatment Methods 0.000 description 1
• 230000000295 complement effect Effects 0.000 description 1
• 230000009918 complex formation Effects 0.000 description 1
• 239000007891 compressed tablet Substances 0.000 description 1
• 230000021615 conjugation Effects 0.000 description 1
• 230000006552 constitutive activation Effects 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• 229910052802 copper Inorganic materials 0.000 description 1
• 210000004351 coronary vessel Anatomy 0.000 description 1
• 230000008878 coupling Effects 0.000 description 1
• 238000010168 coupling process Methods 0.000 description 1
• 238000005859 coupling reaction Methods 0.000 description 1
• 210000004714 cranial suture Anatomy 0.000 description 1
• 239000010779 crude oil Substances 0.000 description 1
• 239000013078 crystal Substances 0.000 description 1
• 108010057085 cytokine receptors Proteins 0.000 description 1
• 230000009089 cytolysis Effects 0.000 description 1
• 238000000354 decomposition reaction Methods 0.000 description 1
• SASYSVUEVMOWPL-NXVVXOECSA-N decyl oleate Chemical compound CCCCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC SASYSVUEVMOWPL-NXVVXOECSA-N 0.000 description 1
• 230000007547 defect Effects 0.000 description 1
• 230000002950 deficient Effects 0.000 description 1
• 230000006735 deficit Effects 0.000 description 1
• 230000018044 dehydration Effects 0.000 description 1
• 238000006297 dehydration reaction Methods 0.000 description 1
• 238000012217 deletion Methods 0.000 description 1
• 230000037430 deletion Effects 0.000 description 1
• 238000004925 denaturation Methods 0.000 description 1
• 230000036425 denaturation Effects 0.000 description 1
• 238000010511 deprotection reaction Methods 0.000 description 1
• 230000003831 deregulation Effects 0.000 description 1
• 231100000223 dermal penetration Toxicity 0.000 description 1
• 238000001514 detection method Methods 0.000 description 1
• 208000033679 diabetic kidney disease Diseases 0.000 description 1
• 235000019700 dicalcium phosphate Nutrition 0.000 description 1
• PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
• 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
• SPWVRYZQLGQKGK-UHFFFAOYSA-N dichloromethane;hexane Chemical compound ClCCl.CCCCCC SPWVRYZQLGQKGK-UHFFFAOYSA-N 0.000 description 1
• 235000014113 dietary fatty acids Nutrition 0.000 description 1
• ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
• 208000028919 diffuse intrinsic pontine glioma Diseases 0.000 description 1
• 208000026144 diffuse midline glioma, H3 K27M-mutant Diseases 0.000 description 1
• 230000029087 digestion Effects 0.000 description 1
• 238000006471 dimerization reaction Methods 0.000 description 1
• MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 1
• 208000016097 disease of metabolism Diseases 0.000 description 1
• 238000004851 dishwashing Methods 0.000 description 1
• 238000004821 distillation Methods 0.000 description 1
• 238000009826 distribution Methods 0.000 description 1
• 230000009189 diving Effects 0.000 description 1
• 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
• 239000002552 dosage form Substances 0.000 description 1
• 238000001647 drug administration Methods 0.000 description 1
• 241001492478 dsDNA viruses, no RNA stage Species 0.000 description 1
• 241001493065 dsRNA viruses Species 0.000 description 1
• 230000009977 dual effect Effects 0.000 description 1
• 201000008184 embryoma Diseases 0.000 description 1
• 239000008387 emulsifying waxe Substances 0.000 description 1
• 150000002081 enamines Chemical class 0.000 description 1
• 230000010595 endothelial cell migration Effects 0.000 description 1
• 108091007231 endothelial receptors Proteins 0.000 description 1
• 210000003038 endothelium Anatomy 0.000 description 1
• 150000002085 enols Chemical class 0.000 description 1
• YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
• 229940116977 epidermal growth factor Drugs 0.000 description 1
• 210000002919 epithelial cell Anatomy 0.000 description 1
• 108700021358 erbB-1 Genes Proteins 0.000 description 1
• 231100000321 erythema Toxicity 0.000 description 1
• 210000003743 erythrocyte Anatomy 0.000 description 1
• 208000006881 esophagitis Diseases 0.000 description 1
• 125000004185 ester group Chemical group 0.000 description 1
• RCXMILPYEKVQLB-UHFFFAOYSA-N ethyl 5-tert-butyl-1h-pyrazole-3-carboxylate Chemical compound CCOC(=O)C=1C=C(C(C)(C)C)NN=1 RCXMILPYEKVQLB-UHFFFAOYSA-N 0.000 description 1
• 125000004494 ethyl ester group Chemical group 0.000 description 1
• PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 1
• GJQLBGWSDGMZKM-UHFFFAOYSA-N ethylhexyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(CC)CCCCC GJQLBGWSDGMZKM-UHFFFAOYSA-N 0.000 description 1
• OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 1
• 238000001704 evaporation Methods 0.000 description 1
• 230000008020 evaporation Effects 0.000 description 1
• 230000007717 exclusion Effects 0.000 description 1
• 230000029142 excretion Effects 0.000 description 1
• 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
• 238000001400 expression cloning Methods 0.000 description 1
• 210000002744 extracellular matrix Anatomy 0.000 description 1
• 238000000605 extraction Methods 0.000 description 1
• 208000030533 eye disease Diseases 0.000 description 1
• 210000000887 face Anatomy 0.000 description 1
• 239000000194 fatty acid Substances 0.000 description 1
• 229930195729 fatty acid Natural products 0.000 description 1
• 150000004665 fatty acids Chemical class 0.000 description 1
• 210000005002 female reproductive tract Anatomy 0.000 description 1
• 239000000835 fiber Substances 0.000 description 1
• 239000000945 filler Substances 0.000 description 1
• 239000012065 filter cake Substances 0.000 description 1
• 239000000706 filtrate Substances 0.000 description 1
• 238000003818 flash chromatography Methods 0.000 description 1
• 235000013312 flour Nutrition 0.000 description 1
• ZHOGHWVKKXUAPI-UHFFFAOYSA-N fluorooxy(phenyl)borinic acid Chemical compound FOB(O)C1=CC=CC=C1 ZHOGHWVKKXUAPI-UHFFFAOYSA-N 0.000 description 1
• 210000001650 focal adhesion Anatomy 0.000 description 1
• 239000011888 foil Substances 0.000 description 1
• 235000013305 food Nutrition 0.000 description 1
• 235000013355 food flavoring agent Nutrition 0.000 description 1
• 230000037406 food intake Effects 0.000 description 1
• 235000019253 formic acid Nutrition 0.000 description 1
• 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
• 239000012634 fragment Substances 0.000 description 1
• 238000013467 fragmentation Methods 0.000 description 1
• 238000006062 fragmentation reaction Methods 0.000 description 1
• 239000012737 fresh medium Substances 0.000 description 1
• NGGMYCMLYOUNGM-CSDLUJIJSA-N fumagillin Chemical class C([C@H]([C@H]([C@@H]1[C@]2(C)[C@H](O2)CC=C(C)C)OC)OC(=O)\C=C\C=C\C=C\C=C\C(O)=O)C[C@@]21CO2 NGGMYCMLYOUNGM-CSDLUJIJSA-N 0.000 description 1
• 239000007789 gas Substances 0.000 description 1
• 239000007903 gelatin capsule Substances 0.000 description 1
• 238000001415 gene therapy Methods 0.000 description 1
• 230000007274 generation of a signal involved in cell-cell signaling Effects 0.000 description 1
• 238000012268 genome sequencing Methods 0.000 description 1
• 229950009672 glembatumumab vedotin Drugs 0.000 description 1
• 208000005017 glioblastoma Diseases 0.000 description 1
• 239000003862 glucocorticoid Substances 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 235000013922 glutamic acid Nutrition 0.000 description 1
• 239000004220 glutamic acid Substances 0.000 description 1
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
• 229960003180 glutathione Drugs 0.000 description 1
• 229940075507 glyceryl monostearate Drugs 0.000 description 1
• 229930182470 glycoside Natural products 0.000 description 1
• 150000002338 glycosides Chemical class 0.000 description 1
• 208000035474 group of disease Diseases 0.000 description 1
• 201000000079 gynecomastia Diseases 0.000 description 1
• 230000003394 haemopoietic effect Effects 0.000 description 1
• 229910052736 halogen Inorganic materials 0.000 description 1
• 125000005843 halogen group Chemical group 0.000 description 1
• BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
• 229960003132 halothane Drugs 0.000 description 1
• 210000003128 head Anatomy 0.000 description 1
• 201000010536 head and neck cancer Diseases 0.000 description 1
• 208000014829 head and neck neoplasm Diseases 0.000 description 1
• 208000019622 heart disease Diseases 0.000 description 1
• 238000010438 heat treatment Methods 0.000 description 1
• 230000009033 hematopoietic malignancy Effects 0.000 description 1
• 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
• 208000034737 hemoglobinopathy Diseases 0.000 description 1
• 230000011132 hemopoiesis Effects 0.000 description 1
• 108700025184 hepatitis B virus X Proteins 0.000 description 1
• 125000000623 heterocyclic group Chemical group 0.000 description 1
• 239000000833 heterodimer Substances 0.000 description 1
• 201000000284 histiocytoma Diseases 0.000 description 1
• 229940088597 hormone Drugs 0.000 description 1
• 108091008039 hormone receptors Proteins 0.000 description 1
• 208000018821 hormone-resistant prostate carcinoma Diseases 0.000 description 1
• 102000046949 human MSC Human genes 0.000 description 1
• 102000058223 human VEGFA Human genes 0.000 description 1
• 102000054584 human Y acceptor Human genes 0.000 description 1
• 108700023876 human Y acceptor Proteins 0.000 description 1
• 208000024697 human cytomegalovirus infection Diseases 0.000 description 1
• 239000001257 hydrogen Substances 0.000 description 1
• 229910052739 hydrogen Inorganic materials 0.000 description 1
• 239000008309 hydrophilic cream Substances 0.000 description 1
• XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
• 229960004171 hydroxychloroquine Drugs 0.000 description 1
• UWYVPFMHMJIBHE-OWOJBTEDSA-N hydroxymaleic acid group Chemical group O/C(/C(=O)O)=C/C(=O)O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
• 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
• UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
• 230000037417 hyperactivation Effects 0.000 description 1
• 208000013403 hyperactivity Diseases 0.000 description 1
• 230000000260 hypercholesteremic effect Effects 0.000 description 1
• 206010020871 hypertrophic cardiomyopathy Diseases 0.000 description 1
• 230000001969 hypertrophic effect Effects 0.000 description 1
• 208000003532 hypothyroidism Diseases 0.000 description 1
• 230000002989 hypothyroidism Effects 0.000 description 1
• KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
• 229960002411 imatinib Drugs 0.000 description 1
• 150000002466 imines Chemical class 0.000 description 1
• 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
• 230000036039 immunity Effects 0.000 description 1
• 230000003053 immunization Effects 0.000 description 1
• 238000002649 immunization Methods 0.000 description 1
• 230000002055 immunohistochemical effect Effects 0.000 description 1
• 238000012744 immunostaining Methods 0.000 description 1
• 229960001438 immunostimulant agent Drugs 0.000 description 1
• 238000009169 immunotherapy Methods 0.000 description 1
• 230000001771 impaired effect Effects 0.000 description 1
• 230000001976 improved effect Effects 0.000 description 1
• 238000011065 in-situ storage Methods 0.000 description 1
• 239000000411 inducer Substances 0.000 description 1
• 230000006698 induction Effects 0.000 description 1
• 230000001939 inductive effect Effects 0.000 description 1
• 208000037797 influenza A Diseases 0.000 description 1
• 238000002664 inhalation therapy Methods 0.000 description 1
• ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
• 239000002054 inoculum Substances 0.000 description 1
• 238000003780 insertion Methods 0.000 description 1
• 230000037431 insertion Effects 0.000 description 1
• 229940125396 insulin Drugs 0.000 description 1
• XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 1
• 229940096397 interleukin-8 Drugs 0.000 description 1
• 238000001361 intraarterial administration Methods 0.000 description 1
• 230000032631 intramembranous ossification Effects 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• 150000002500 ions Chemical class 0.000 description 1
• 230000001788 irregular Effects 0.000 description 1
• 208000028867 ischemia Diseases 0.000 description 1
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
• 229940078545 isocetyl stearate Drugs 0.000 description 1
• 229960002725 isoflurane Drugs 0.000 description 1
• 238000002955 isolation Methods 0.000 description 1
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 238000012804 iterative process Methods 0.000 description 1
• 150000002576 ketones Chemical class 0.000 description 1
• 201000010982 kidney cancer Diseases 0.000 description 1
• 210000003127 knee Anatomy 0.000 description 1
• 238000011005 laboratory method Methods 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 210000001821 langerhans cell Anatomy 0.000 description 1
• 201000005264 laryngeal carcinoma Diseases 0.000 description 1
• 201000010901 lateral sclerosis Diseases 0.000 description 1
• 210000002414 leg Anatomy 0.000 description 1
• 230000003902 lesion Effects 0.000 description 1
• 238000012417 linear regression Methods 0.000 description 1
• 230000002366 lipolytic effect Effects 0.000 description 1
• 229940057995 liquid paraffin Drugs 0.000 description 1
• GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 1
• 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 1
• 230000004807 localization Effects 0.000 description 1
• 201000005202 lung cancer Diseases 0.000 description 1
• 208000020816 lung neoplasm Diseases 0.000 description 1
• 208000037841 lung tumor Diseases 0.000 description 1
• 206010025135 lupus erythematosus Diseases 0.000 description 1
• 210000002751 lymph Anatomy 0.000 description 1
• 210000004324 lymphatic system Anatomy 0.000 description 1
• 208000017830 lymphoblastoma Diseases 0.000 description 1
• 230000000527 lymphocytic effect Effects 0.000 description 1
• 239000011777 magnesium Substances 0.000 description 1
• 229910052749 magnesium Inorganic materials 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• 201000010117 malignant biphasic mesothelioma Diseases 0.000 description 1
• 201000002350 malignant ciliary body melanoma Diseases 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 230000000873 masking effect Effects 0.000 description 1
• 239000011159 matrix material Substances 0.000 description 1
• 230000035800 maturation Effects 0.000 description 1
• 201000000638 mature B-cell neoplasm Diseases 0.000 description 1
• 210000001370 mediastinum Anatomy 0.000 description 1
• 229960003194 meglumine Drugs 0.000 description 1
• 210000002752 melanocyte Anatomy 0.000 description 1
• 238000002844 melting Methods 0.000 description 1
• 230000008018 melting Effects 0.000 description 1
• 230000028161 membrane depolarization Effects 0.000 description 1
• 230000005906 menstruation Effects 0.000 description 1
• 238000000694 mesotherapy Methods 0.000 description 1
• 208000030159 metabolic disease Diseases 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 230000037353 metabolic pathway Effects 0.000 description 1
• 239000002207 metabolite Substances 0.000 description 1
• 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
• 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
• LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
• KNPNGMXRGITFLE-UHFFFAOYSA-N methylperoxy(phenyl)borinic acid Chemical compound COOB(O)C1=CC=CC=C1 KNPNGMXRGITFLE-UHFFFAOYSA-N 0.000 description 1
• 229940016286 microcrystalline cellulose Drugs 0.000 description 1
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
• 239000008108 microcrystalline cellulose Substances 0.000 description 1
• 239000011859 microparticle Substances 0.000 description 1
• 206010027599 migraine Diseases 0.000 description 1
• 230000005012 migration Effects 0.000 description 1
• 238000013508 migration Methods 0.000 description 1
• 239000002480 mineral oil Substances 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• 230000000116 mitigating effect Effects 0.000 description 1
• 230000003020 moisturizing effect Effects 0.000 description 1
• 239000007932 molded tablet Substances 0.000 description 1
• 230000009456 molecular mechanism Effects 0.000 description 1
• 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
• 210000005087 mononuclear cell Anatomy 0.000 description 1
• 230000004899 motility Effects 0.000 description 1
• 208000005264 motor neuron disease Diseases 0.000 description 1
• 239000002324 mouth wash Substances 0.000 description 1
• 210000004877 mucosa Anatomy 0.000 description 1
• 210000003097 mucus Anatomy 0.000 description 1
• 210000003205 muscle Anatomy 0.000 description 1
• 210000000663 muscle cell Anatomy 0.000 description 1
• 239000003471 mutagenic agent Substances 0.000 description 1
• 231100000707 mutagenic chemical Toxicity 0.000 description 1
• 230000003505 mutagenic effect Effects 0.000 description 1
• 230000000869 mutational effect Effects 0.000 description 1
• 206010028417 myasthenia gravis Diseases 0.000 description 1
• 208000025113 myeloid leukemia Diseases 0.000 description 1
• 230000002071 myeloproliferative effect Effects 0.000 description 1
• 210000004165 myocardium Anatomy 0.000 description 1
• 229940043348 myristyl alcohol Drugs 0.000 description 1
• 208000009091 myxoma Diseases 0.000 description 1
• PWDYHMBTPGXCSN-VCBMUGGBSA-N n,n'-bis[3,5-bis[(e)-n-(diaminomethylideneamino)-c-methylcarbonimidoyl]phenyl]decanediamide Chemical compound NC(N)=N/N=C(\C)C1=CC(C(=N/N=C(N)N)/C)=CC(NC(=O)CCCCCCCCC(=O)NC=2C=C(C=C(C=2)C(\C)=N\N=C(N)N)C(\C)=N\N=C(N)N)=C1 PWDYHMBTPGXCSN-VCBMUGGBSA-N 0.000 description 1
• 229940100662 nasal drops Drugs 0.000 description 1
• 239000007922 nasal spray Substances 0.000 description 1
• 229940097496 nasal spray Drugs 0.000 description 1
• 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
• 239000006199 nebulizer Substances 0.000 description 1
• 230000001338 necrotic effect Effects 0.000 description 1
• 230000014399 negative regulation of angiogenesis Effects 0.000 description 1
• 230000017095 negative regulation of cell growth Effects 0.000 description 1
• 230000013152 negative regulation of cell migration Effects 0.000 description 1
• 230000031990 negative regulation of inflammatory response Effects 0.000 description 1
• 208000010915 neoplasm of mature B-cells Diseases 0.000 description 1
• 210000005036 nerve Anatomy 0.000 description 1
• 230000008764 nerve damage Effects 0.000 description 1
• 206010061311 nervous system neoplasm Diseases 0.000 description 1
• 230000001272 neurogenic effect Effects 0.000 description 1
• 230000003959 neuroinflammation Effects 0.000 description 1
• 230000000926 neurological effect Effects 0.000 description 1
• 230000002232 neuromuscular Effects 0.000 description 1
• 230000004112 neuroprotection Effects 0.000 description 1
• 230000003472 neutralizing effect Effects 0.000 description 1
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
• 125000000018 nitroso group Chemical group N(=O)* 0.000 description 1
• 201000000032 nodular malignant melanoma Diseases 0.000 description 1
• 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
• 201000002575 ocular melanoma Diseases 0.000 description 1
• 239000003883 ointment base Substances 0.000 description 1
• ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 235000005985 organic acids Nutrition 0.000 description 1
• 150000002892 organic cations Chemical class 0.000 description 1
• 150000002894 organic compounds Chemical class 0.000 description 1
• 239000012074 organic phase Substances 0.000 description 1
• 210000002997 osteoclast Anatomy 0.000 description 1
• 230000002188 osteogenic effect Effects 0.000 description 1
• 238000012261 overproduction Methods 0.000 description 1
• 230000016087 ovulation Effects 0.000 description 1
• 230000003647 oxidation Effects 0.000 description 1
• 238000007254 oxidation reaction Methods 0.000 description 1
• 150000002923 oximes Chemical class 0.000 description 1
• IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
• RUVINXPYWBROJD-UHFFFAOYSA-N para-methoxyphenyl Natural products COC1=CC=C(C=CC)C=C1 RUVINXPYWBROJD-UHFFFAOYSA-N 0.000 description 1
• 230000003076 paracrine Effects 0.000 description 1
• 239000002245 particle Substances 0.000 description 1
• 239000013618 particulate matter Substances 0.000 description 1
• 244000052769 pathogen Species 0.000 description 1
• 230000001575 pathological effect Effects 0.000 description 1
• 230000001991 pathophysiological effect Effects 0.000 description 1
• ACNHBCIZLNNLRS-UBGQALKQSA-N paxilline Chemical compound N1C2=CC=CC=C2C2=C1[C@]1(C)[C@@]3(C)CC[C@@H]4O[C@H](C(C)(O)C)C(=O)C=C4[C@]3(O)CC[C@H]1C2 ACNHBCIZLNNLRS-UBGQALKQSA-N 0.000 description 1
• 239000008188 pellet Substances 0.000 description 1
• 210000004197 pelvis Anatomy 0.000 description 1
• 230000000149 penetrating effect Effects 0.000 description 1
• 230000002093 peripheral effect Effects 0.000 description 1
• 201000005528 peripheral nervous system neoplasm Diseases 0.000 description 1
• 201000002524 peritoneal carcinoma Diseases 0.000 description 1
• 210000001539 phagocyte Anatomy 0.000 description 1
• 229940124531 pharmaceutical excipient Drugs 0.000 description 1
• WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
• WSJJUZNTRZTWIN-UHFFFAOYSA-N phenylmethanamine Chemical compound NCC1=CC=CC=C1.NCC1=CC=CC=C1 WSJJUZNTRZTWIN-UHFFFAOYSA-N 0.000 description 1
• 108010016216 phosphatidylinositol receptors Proteins 0.000 description 1
• 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 1
• 150000003053 piperidines Chemical class 0.000 description 1
• 230000003169 placental effect Effects 0.000 description 1
• 231100000614 poison Toxicity 0.000 description 1
• 230000007096 poisonous effect Effects 0.000 description 1
• 229920001223 polyethylene glycol Polymers 0.000 description 1
• 150000003077 polyols Chemical class 0.000 description 1
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
• 229940069328 povidone Drugs 0.000 description 1
• YSVQLWJDHYBITL-UHFFFAOYSA-N ppse Chemical compound C[Si](C)(C)OP(=O)=O YSVQLWJDHYBITL-UHFFFAOYSA-N 0.000 description 1
• 108010074732 preproenkephalin Proteins 0.000 description 1
• 230000002335 preservative effect Effects 0.000 description 1
• 238000003825 pressing Methods 0.000 description 1
• 230000003449 preventive effect Effects 0.000 description 1
• 150000003138 primary alcohols Chemical class 0.000 description 1
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
• 210000002248 primary sensory neuron Anatomy 0.000 description 1
• 230000005522 programmed cell death Effects 0.000 description 1
• 230000000770 proinflammatory effect Effects 0.000 description 1
• 230000001737 promoting effect Effects 0.000 description 1
• AMMGCGVWJMRTQI-UHFFFAOYSA-N prop-1-en-2-yl carbonochloridate Chemical compound CC(=C)OC(Cl)=O AMMGCGVWJMRTQI-UHFFFAOYSA-N 0.000 description 1
• CZMAXQOXGAWNDO-UHFFFAOYSA-N propane-1,1,2-triol Chemical compound CC(O)C(O)O CZMAXQOXGAWNDO-UHFFFAOYSA-N 0.000 description 1
• KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 1
• 239000003380 propellant Substances 0.000 description 1
• 230000000069 prophylactic effect Effects 0.000 description 1
• 238000011321 prophylaxis Methods 0.000 description 1
• 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
• 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
• QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
• 230000002633 protecting effect Effects 0.000 description 1
• 230000001012 protector Effects 0.000 description 1
• 230000005180 public health Effects 0.000 description 1
• 208000002815 pulmonary hypertension Diseases 0.000 description 1
• 125000004289 pyrazol-3-yl group Chemical group [H]N1N=C(*)C([H])=C1[H] 0.000 description 1
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
• YEYHFKBVNARCNE-UHFFFAOYSA-N pyrido[2,3-b]pyrazine Chemical compound N1=CC=NC2=CC=CN=C21 YEYHFKBVNARCNE-UHFFFAOYSA-N 0.000 description 1
• 238000011002 quantification Methods 0.000 description 1
• 125000001453 quaternary ammonium group Chemical group 0.000 description 1
• 229960001404 quinidine Drugs 0.000 description 1
• 230000005855 radiation Effects 0.000 description 1
• 230000002285 radioactive effect Effects 0.000 description 1
• 238000001959 radiotherapy Methods 0.000 description 1
• 102000001720 ral Guanine Nucleotide Exchange Factor Human genes 0.000 description 1
• 108010029592 ral Guanine Nucleotide Exchange Factor Proteins 0.000 description 1
• 239000000376 reactant Substances 0.000 description 1
• 230000007420 reactivation Effects 0.000 description 1
• 208000002574 reactive arthritis Diseases 0.000 description 1
• 230000008707 rearrangement Effects 0.000 description 1
• 201000001275 rectum cancer Diseases 0.000 description 1
• 230000009703 regulation of cell differentiation Effects 0.000 description 1
• 230000021014 regulation of cell growth Effects 0.000 description 1
• 230000025053 regulation of cell proliferation Effects 0.000 description 1
• 210000003289 regulatory T cell Anatomy 0.000 description 1
• 238000007634 remodeling Methods 0.000 description 1
• 201000010174 renal carcinoma Diseases 0.000 description 1
• 230000010410 reperfusion Effects 0.000 description 1
• 230000010076 replication Effects 0.000 description 1
• 208000017443 reproductive system disease Diseases 0.000 description 1
• 239000011347 resin Substances 0.000 description 1
• 229920005989 resin Polymers 0.000 description 1
• 230000008261 resistance mechanism Effects 0.000 description 1
• 230000000241 respiratory effect Effects 0.000 description 1
• 210000001525 retina Anatomy 0.000 description 1
• 210000001957 retinal vein Anatomy 0.000 description 1
• 210000001210 retinal vessel Anatomy 0.000 description 1
• 102200006541 rs121913530 Human genes 0.000 description 1
• 201000005404 rubella Diseases 0.000 description 1
• YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
• 229960001860 salicylate Drugs 0.000 description 1
• 238000009938 salting Methods 0.000 description 1
• 210000002235 sarcomere Anatomy 0.000 description 1
• 239000012047 saturated solution Substances 0.000 description 1
• 238000012216 screening Methods 0.000 description 1
• 238000010956 selective crystallization Methods 0.000 description 1
• 229950011005 semapimod Drugs 0.000 description 1
• 230000001953 sensory effect Effects 0.000 description 1
• 238000000926 separation method Methods 0.000 description 1
• 238000013207 serial dilution Methods 0.000 description 1
• 210000002966 serum Anatomy 0.000 description 1
• 238000007493 shaping process Methods 0.000 description 1
• 208000007056 sickle cell anemia Diseases 0.000 description 1
• 108091006024 signal transducing proteins Proteins 0.000 description 1
• 102000034285 signal transducing proteins Human genes 0.000 description 1
• 239000000377 silicon dioxide Substances 0.000 description 1
• RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
• 229960002855 simvastatin Drugs 0.000 description 1
• 238000009097 single-agent therapy Methods 0.000 description 1
• 230000012488 skeletal system development Effects 0.000 description 1
• 230000035483 skin reaction Effects 0.000 description 1
• 231100000430 skin reaction Toxicity 0.000 description 1
• 201000010106 skin squamous cell carcinoma Diseases 0.000 description 1
• 239000002893 slag Substances 0.000 description 1
• 239000010454 slate Substances 0.000 description 1
• 102000030938 small GTPase Human genes 0.000 description 1
• 108060007624 small GTPase Proteins 0.000 description 1
• 150000003384 small molecules Chemical class 0.000 description 1
• AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 239000012279 sodium borohydride Substances 0.000 description 1
• 229910000033 sodium borohydride Inorganic materials 0.000 description 1
• 239000012265 solid product Substances 0.000 description 1
• 229960003787 sorafenib Drugs 0.000 description 1
• 208000005801 spondylosis Diseases 0.000 description 1
• 230000002269 spontaneous effect Effects 0.000 description 1
• 238000005507 spraying Methods 0.000 description 1
• 230000007480 spreading Effects 0.000 description 1
• 238000003892 spreading Methods 0.000 description 1
• 208000014559 squamous cell carcinoma of lip Diseases 0.000 description 1
• 241001147420 ssDNA viruses Species 0.000 description 1
• 230000006641 stabilisation Effects 0.000 description 1
• 238000011105 stabilization Methods 0.000 description 1
• 230000000087 stabilizing effect Effects 0.000 description 1
• 239000007858 starting material Substances 0.000 description 1
• 210000004500 stellate cell Anatomy 0.000 description 1
• 239000003270 steroid hormone Substances 0.000 description 1
• 230000004936 stimulating effect Effects 0.000 description 1
• 230000000638 stimulation Effects 0.000 description 1
• 238000003860 storage Methods 0.000 description 1
• 238000013517 stratification Methods 0.000 description 1
• 210000003699 striated muscle Anatomy 0.000 description 1
• 208000023516 stroke disease Diseases 0.000 description 1
• 210000002536 stromal cell Anatomy 0.000 description 1
• 125000001424 substituent group Chemical group 0.000 description 1
• 150000005846 sugar alcohols Polymers 0.000 description 1
• 229910052717 sulfur Inorganic materials 0.000 description 1
• 239000011593 sulfur Substances 0.000 description 1
• 239000000375 suspending agent Substances 0.000 description 1
• 238000013268 sustained release Methods 0.000 description 1
• 239000012730 sustained-release form Substances 0.000 description 1
• 230000000946 synaptic effect Effects 0.000 description 1
• 230000002195 synergetic effect Effects 0.000 description 1
• 210000002437 synoviocyte Anatomy 0.000 description 1
• 201000004595 synovitis Diseases 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
• 229920002258 tannic acid Polymers 0.000 description 1
• 235000015523 tannic acid Nutrition 0.000 description 1
• 229940033123 tannic acid Drugs 0.000 description 1
• 208000001608 teratocarcinoma Diseases 0.000 description 1
• 108091008743 testicular receptors 4 Proteins 0.000 description 1
• 229940124597 therapeutic agent Drugs 0.000 description 1
• 238000009210 therapy by ultrasound Methods 0.000 description 1
• 230000000476 thermogenic effect Effects 0.000 description 1
• 239000002562 thickening agent Substances 0.000 description 1
• 208000013077 thyroid gland carcinoma Diseases 0.000 description 1
• 208000021510 thyroid gland disease Diseases 0.000 description 1
• 208000019179 thyroid gland undifferentiated (anaplastic) carcinoma Diseases 0.000 description 1
• 201000006134 tongue cancer Diseases 0.000 description 1
• 208000004371 toothache Diseases 0.000 description 1
• 239000012049 topical pharmaceutical composition Substances 0.000 description 1
• 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
• 231100000331 toxic Toxicity 0.000 description 1
• 230000002588 toxic effect Effects 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 239000003053 toxin Substances 0.000 description 1
• 231100000765 toxin Toxicity 0.000 description 1
• 108700012359 toxins Proteins 0.000 description 1
• 239000000196 tragacanth Substances 0.000 description 1
• 235000010487 tragacanth Nutrition 0.000 description 1
• 229940116362 tragacanth Drugs 0.000 description 1
• 102000014898 transaminase activity proteins Human genes 0.000 description 1
• 238000012546 transfer Methods 0.000 description 1
• 230000009466 transformation Effects 0.000 description 1
• 238000011830 transgenic mouse model Methods 0.000 description 1
• 206010044412 transitional cell carcinoma Diseases 0.000 description 1
• 102000027257 transmembrane receptors Human genes 0.000 description 1
• 108091008578 transmembrane receptors Proteins 0.000 description 1
• 230000008733 trauma Effects 0.000 description 1
• 238000011269 treatment regimen Methods 0.000 description 1
• YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
• 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
• 206010044652 trigeminal neuralgia Diseases 0.000 description 1
• UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 1
• GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
• 229960000281 trometamol Drugs 0.000 description 1
• 208000037972 tropical disease Diseases 0.000 description 1
• 208000006961 tropical spastic paraparesis Diseases 0.000 description 1
• 239000012588 trypsin Substances 0.000 description 1
• 210000005239 tubule Anatomy 0.000 description 1
• 230000005747 tumor angiogenesis Effects 0.000 description 1
• 230000005748 tumor development Effects 0.000 description 1
• 230000005751 tumor progression Effects 0.000 description 1
• 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
• 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
• 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
• 108010002164 tyrosine receptor Proteins 0.000 description 1
• 238000000825 ultraviolet detection Methods 0.000 description 1
• 241000701447 unidentified baculovirus Species 0.000 description 1
• 241001430294 unidentified retrovirus Species 0.000 description 1
• 238000011144 upstream manufacturing Methods 0.000 description 1
• 150000003672 ureas Chemical class 0.000 description 1
• 208000009852 uremia Diseases 0.000 description 1
• 201000007433 ureter carcinoma Diseases 0.000 description 1
• VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
• 208000023747 urothelial carcinoma Diseases 0.000 description 1
• 210000001215 vagina Anatomy 0.000 description 1
• 230000025033 vasoconstriction Effects 0.000 description 1
• 235000015112 vegetable and seed oil Nutrition 0.000 description 1
• 239000008158 vegetable oil Substances 0.000 description 1
• 210000000264 venule Anatomy 0.000 description 1
• 210000003501 vero cell Anatomy 0.000 description 1
• 230000029812 viral genome replication Effects 0.000 description 1
• 230000003612 virological effect Effects 0.000 description 1
• 230000000007 visual effect Effects 0.000 description 1
• 208000030401 vitamin deficiency disease Diseases 0.000 description 1
• 239000003039 volatile agent Substances 0.000 description 1
• 239000008215 water for injection Substances 0.000 description 1
• 239000001993 wax Substances 0.000 description 1
• 238000005303 weighing Methods 0.000 description 1
• 238000009736 wetting Methods 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1